US20200199136A1 - Pikfyve kinase inhibitors - Google Patents
Pikfyve kinase inhibitors Download PDFInfo
- Publication number
- US20200199136A1 US20200199136A1 US16/641,159 US201816641159A US2020199136A1 US 20200199136 A1 US20200199136 A1 US 20200199136A1 US 201816641159 A US201816641159 A US 201816641159A US 2020199136 A1 US2020199136 A1 US 2020199136A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- compound
- unsubstituted
- virus
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 5
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 139
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 claims abstract description 22
- 101710145421 1-phosphatidylinositol 3-phosphate 5-kinase Proteins 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 70
- -1 3-trifluoromethylphenyl Chemical group 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 208000012902 Nervous system disease Diseases 0.000 claims description 21
- 208000025966 Neurological disease Diseases 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 208000036142 Viral infection Diseases 0.000 claims description 11
- 230000009385 viral infection Effects 0.000 claims description 11
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 9
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 9
- 241001115401 Marburgvirus Species 0.000 claims description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 8
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 8
- 241000701460 JC polyomavirus Species 0.000 claims description 8
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 8
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 8
- 241001115402 Ebolavirus Species 0.000 claims description 7
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 6
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 150000002926 oxygen Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910004749 OS(O)2 Inorganic materials 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 101710143522 1-phosphatidylinositol 3-phosphate 5-kinase FAB1 Proteins 0.000 abstract description 3
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 42
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 239000012071 phase Substances 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 0 *.CC.[1*]CC1=NC(CC)=CC([3*])=N1 Chemical compound *.CC.[1*]CC1=NC(CC)=CC([3*])=N1 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- JAZQIOZMPNVSII-UHFFFAOYSA-N 5-(3-methoxyphenyl)-1h-pyrazole Chemical compound COC1=CC=CC(C=2NN=CC=2)=C1 JAZQIOZMPNVSII-UHFFFAOYSA-N 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
- 229950002889 apilimod Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 description 7
- 208000003950 B-cell lymphoma Diseases 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- IJORKQHYSXFHGL-DHIUTWEWSA-N (3aR,6aR)-4-[6-(3-phenylpyrazol-1-yl)-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound C1(=CC=CC=C1)C1=NN(C=C1)C1=CC(=NC(=N1)OCCC1=NC=CC=C1)N1[C@H]2[C@@H](CC1)OCC2 IJORKQHYSXFHGL-DHIUTWEWSA-N 0.000 description 5
- LSVYQCHYHRHVHT-FGZHOGPDSA-N (3aR,6aR)-4-[6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound COC=1C=C(C=CC=1)C1=NN(C=C1)C1=CC(=NC(=N1)OCCC1=C(N=CS1)C)N1[C@H]2[C@@H](CC1)OCC2 LSVYQCHYHRHVHT-FGZHOGPDSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- DROUVIKCNOHKBA-UHFFFAOYSA-N 4,6-dichloro-2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC(Cl)=CC(Cl)=N1 DROUVIKCNOHKBA-UHFFFAOYSA-N 0.000 description 5
- OXONLQNMMOKVDS-UHFFFAOYSA-N 4-[4-[3-(3-methoxyphenyl)pyrazol-1-yl]-6-morpholin-4-ylpyrimidin-2-yl]oxybutane-1,2-diol Chemical compound COc1cccc(c1)-c1ccn(n1)-c1cc(nc(OCCC(O)CO)n1)N1CCOCC1 OXONLQNMMOKVDS-UHFFFAOYSA-N 0.000 description 5
- DMFBVFXMSUEQCX-UHFFFAOYSA-N 4-[6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]pyrimidin-4-yl]morpholine Chemical compound COC=1C=C(C=CC=1)C1=NN(C=C1)C1=CC(=NC(=N1)OCCC1=C(N=CS1)C)N1CCOCC1 DMFBVFXMSUEQCX-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- JEHHRDKAAJOADB-LTGQRPFBSA-N 4-[4-[(3aR,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrol-4-yl]-6-[3-(3-methoxyphenyl)pyrazol-1-yl]pyrimidin-2-yl]oxybutane-1,2-diol Chemical compound O1CC[C@H]2N(CC[C@H]21)C1=NC(=NC(=C1)N1N=C(C=C1)C1=CC(=CC=C1)OC)OCCC(CO)O JEHHRDKAAJOADB-LTGQRPFBSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- BOXIBNQQPLWNOP-UHFFFAOYSA-N 4-[6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]morpholine Chemical compound COC=1C=C(C=CC=1)C1=NN(C=C1)C1=CC(=NC(=N1)OCC1OCCC1)N1CCOCC1 BOXIBNQQPLWNOP-UHFFFAOYSA-N 0.000 description 3
- KFHNXAWOFZLGLW-UHFFFAOYSA-N 4-[6-[4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]morpholine Chemical compound CC1=CC=CC(=C1)C1=CSC(=N1)C1=NC(OCC2CCCO2)=NC(=C1)N1CCOCC1 KFHNXAWOFZLGLW-UHFFFAOYSA-N 0.000 description 3
- OJHVOOQKMGLGHE-UHFFFAOYSA-N 4-chloro-6-[3-(3-methylphenyl)pyrazol-1-yl]-2-(oxolan-2-ylmethoxy)pyrimidine Chemical compound Cc1cccc(c1)-c1ccn(n1)-c1cc(Cl)nc(OCC2CCCO2)n1 OJHVOOQKMGLGHE-UHFFFAOYSA-N 0.000 description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101100174573 Homo sapiens PIKFYVE gene Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- BDMWJZIDHNKGMH-RKDXNWHRSA-N [H][C@@]12CCN(C(C)C)[C@]1([H])CCO2 Chemical compound [H][C@@]12CCN(C(C)C)[C@]1([H])CCO2 BDMWJZIDHNKGMH-RKDXNWHRSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000009104 chemotherapy regimen Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- KUXRFVCSRRAVEW-NHCUHLMSSA-N (3aR,6aR)-4-[6-(3-phenylpyrazol-1-yl)-2-(2-pyrimidin-2-ylethyl)pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound C1(=CC=CC=C1)C1=NN(C=C1)C1=CC(=NC(=N1)CCC1=NC=CC=N1)N1[C@H]2[C@@H](CC1)OCC2 KUXRFVCSRRAVEW-NHCUHLMSSA-N 0.000 description 2
- IIYSBNYLQJWVRY-DNQXCXABSA-N (3aR,6aR)-4-[6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound COc1cccc(c1)-c1ccn(n1)-c1cc(nc(OCCc2ccccn2)n1)N1CC[C@H]2OCC[C@@H]12 IIYSBNYLQJWVRY-DNQXCXABSA-N 0.000 description 2
- DCVCJLYHZZJHEW-IPKCRJEZSA-N (3aR,6aR)-4-[6-[4-(3-methylphenyl)-1,3-thiazol-2-yl]-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound O1C(CCC1)COC1=NC(=CC(=N1)N1[C@H]2[C@@H](CC1)OCC2)C=1SC=C(N=1)C=1C=C(C=CC=1)C DCVCJLYHZZJHEW-IPKCRJEZSA-N 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- CGYMNXMAUZMIJL-UHFFFAOYSA-N *.CC.CCC(C)C Chemical compound *.CC.CCC(C)C CGYMNXMAUZMIJL-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 102000001556 1-Phosphatidylinositol 4-Kinase Human genes 0.000 description 2
- 108010029190 1-Phosphatidylinositol 4-Kinase Proteins 0.000 description 2
- MDGHHHYENBEPDH-RTBURBONSA-N 2-[4-[(3aR,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrol-4-yl]-6-[3-(3-methoxyphenyl)pyrazol-1-yl]pyrimidin-2-yl]oxyethanol Chemical compound COc1cccc(c1)-c1ccn(n1)-c1cc(nc(OCCO)n1)N1CC[C@H]2OCC[C@@H]12 MDGHHHYENBEPDH-RTBURBONSA-N 0.000 description 2
- WNGALIVVWSRMMV-UHFFFAOYSA-N 2-bromo-4-(3-methylphenyl)-1,3-thiazole Chemical compound CC1=CC=CC(C=2N=C(Br)SC=2)=C1 WNGALIVVWSRMMV-UHFFFAOYSA-N 0.000 description 2
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 2
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- BXGYBSJAZFGIPX-UHFFFAOYSA-N 2-pyridin-2-ylethanol Chemical compound OCCC1=CC=CC=N1 BXGYBSJAZFGIPX-UHFFFAOYSA-N 0.000 description 2
- FTDVBWLZOVWLRN-UHFFFAOYSA-N 4,6-dichloro-2-(oxolan-2-ylmethoxy)pyrimidine Chemical compound ClC1=NC(=NC(=C1)Cl)OCC1OCCC1 FTDVBWLZOVWLRN-UHFFFAOYSA-N 0.000 description 2
- RDKOPRHNUJPBJD-UHFFFAOYSA-N 4-[3-(3-methylphenyl)pyrazol-1-yl]-6-(oxolan-3-yl)-2-(oxolan-2-ylmethoxy)pyrimidine Chemical compound CC1=CC=CC(=C1)C1=NN(C=C1)C1=NC(OCC2CCCO2)=NC(=C1)C1CCOC1 RDKOPRHNUJPBJD-UHFFFAOYSA-N 0.000 description 2
- JZADLGVCONAVOW-UHFFFAOYSA-N 4-[6-(4-phenylimidazol-1-yl)-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]morpholine Chemical compound C1(=CC=CC=C1)C=1N=CN(C=1)C1=CC(=NC(=N1)OCCC1=NC=CC=C1)N1CCOCC1 JZADLGVCONAVOW-UHFFFAOYSA-N 0.000 description 2
- KDTBJFRHHSFZEC-UHFFFAOYSA-N 4-[6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-[2-(oxan-4-yl)ethoxy]pyrimidin-4-yl]morpholine Chemical compound COC=1C=C(C=CC=1)C1=NN(C=C1)C1=CC(=NC(=N1)OCCC1CCOCC1)N1CCOCC1 KDTBJFRHHSFZEC-UHFFFAOYSA-N 0.000 description 2
- ZDMUNRMLASAPGY-UHFFFAOYSA-N 4-[6-chloro-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]morpholine Chemical compound ClC1=NC(OCC2CCCO2)=NC(=C1)N1CCOCC1 ZDMUNRMLASAPGY-UHFFFAOYSA-N 0.000 description 2
- 125000005986 4-piperidonyl group Chemical group 0.000 description 2
- NRWSHDHOQDSARY-UHFFFAOYSA-N 5-(3-methylphenyl)-1h-pyrazole Chemical compound CC1=CC=CC(C2=NNC=C2)=C1 NRWSHDHOQDSARY-UHFFFAOYSA-N 0.000 description 2
- OEDUIFSDODUDRK-UHFFFAOYSA-N 5-phenyl-1h-pyrazole Chemical compound N1N=CC=C1C1=CC=CC=C1 OEDUIFSDODUDRK-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000024956 Borna Disease Diseases 0.000 description 2
- 241000724653 Borna disease virus Species 0.000 description 2
- RLAFBLDLQYPUKW-UZKZOWQRSA-N C1=CC=C(C2=CN(C3=CC(N4CCOCC4)=NC(OCCC4=NC=CC=C4)=N3)N=C2)C=C1.CC1=CC=CC(C2=CSC(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)=N2)=C1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(C4=NC(C5=CC(C)=CC=C5)=CS4)=C3)[C@]1([H])CCO2 Chemical compound C1=CC=C(C2=CN(C3=CC(N4CCOCC4)=NC(OCCC4=NC=CC=C4)=N3)N=C2)C=C1.CC1=CC=CC(C2=CSC(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)=N2)=C1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(C4=NC(C5=CC(C)=CC=C5)=CS4)=C3)[C@]1([H])CCO2 RLAFBLDLQYPUKW-UZKZOWQRSA-N 0.000 description 2
- KETMIALRGOMQLB-UHFFFAOYSA-N C=CC(=C)C1=NCC(NC(C)C)=C1.CC(C)C(=O)NC1=NC=CC=C1.CC(C)C1=NCC2(CCCC2)C1.CC(C)N1C(=O)NC2=C1/C=C\C=C/2.CC(C)N1C=NC2=C1C=CC=C2.CC(C)N1N=CC2=C1C=CC=C2.CC(C)NC(=O)C1=CC=CC=C1.CC(C)NC1=NC=CC=N1.CC(C)NC1=NN=CC=C1.CC(C)NC1=NNC2=C1C=CC=C2.CC1=CN(C(C)C)N=C1C Chemical compound C=CC(=C)C1=NCC(NC(C)C)=C1.CC(C)C(=O)NC1=NC=CC=C1.CC(C)C1=NCC2(CCCC2)C1.CC(C)N1C(=O)NC2=C1/C=C\C=C/2.CC(C)N1C=NC2=C1C=CC=C2.CC(C)N1N=CC2=C1C=CC=C2.CC(C)NC(=O)C1=CC=CC=C1.CC(C)NC1=NC=CC=N1.CC(C)NC1=NN=CC=C1.CC(C)NC1=NNC2=C1C=CC=C2.CC1=CN(C(C)C)N=C1C KETMIALRGOMQLB-UHFFFAOYSA-N 0.000 description 2
- PQTZCZBMSXQWLF-UHFFFAOYSA-N CC(C)C(=O)C1=CC=CC=C1.CC(C)C1=CN(C(C)C)N=C1.CC(C)C1=NN(C(C)C)C=C1.CC(C)N1C=CC(C2=CC=CC(C(F)(F)F)=C2)=N1.CC(C)N1C=CC(C2=CC=CC(Cl)=C2)=N1.CC(C)N1C=CC(C2=CC=CC=C2)=N1.CC(C)N1C=NC(C2=CC=CC=C2)=C1.CC1=CC(C2=CN=C(C(C)C)O2)=CC=C1.CC1=CC(C2=NC(C(C)C)=NO2)=CC=C1.CC1=CC=CC(C2=CN(C(C)C)N=N2)=C1.CC1=CC=CC(C2=CSC(C(C)C)=N2)=C1.CC1=CC=CC(C2=NN(C(C)C)C=C2)=C1.CC1=CC=CC(N2=NC(C(C)C)C=C2)=C1.CC1=CC=CC(N2C=CC(C(C)C)=N2)=C1.CC1=CC=CC=C1C1=NN(C(C)C)C=C1.COC1=CC(C2=NN(C(C)C)C=C2)=CC=C1 Chemical compound CC(C)C(=O)C1=CC=CC=C1.CC(C)C1=CN(C(C)C)N=C1.CC(C)C1=NN(C(C)C)C=C1.CC(C)N1C=CC(C2=CC=CC(C(F)(F)F)=C2)=N1.CC(C)N1C=CC(C2=CC=CC(Cl)=C2)=N1.CC(C)N1C=CC(C2=CC=CC=C2)=N1.CC(C)N1C=NC(C2=CC=CC=C2)=C1.CC1=CC(C2=CN=C(C(C)C)O2)=CC=C1.CC1=CC(C2=NC(C(C)C)=NO2)=CC=C1.CC1=CC=CC(C2=CN(C(C)C)N=N2)=C1.CC1=CC=CC(C2=CSC(C(C)C)=N2)=C1.CC1=CC=CC(C2=NN(C(C)C)C=C2)=C1.CC1=CC=CC(N2=NC(C(C)C)C=C2)=C1.CC1=CC=CC(N2C=CC(C(C)C)=N2)=C1.CC1=CC=CC=C1C1=NN(C(C)C)C=C1.COC1=CC(C2=NN(C(C)C)C=C2)=CC=C1 PQTZCZBMSXQWLF-UHFFFAOYSA-N 0.000 description 2
- VKSJFURIRILEFB-UHFFFAOYSA-N CC(C)C1=CC=CC=N1.CC(C)C1=NC=CC=N1.CC(C)C1=[SH]C=NC1C.CC(C)C1CCCCC1.CC(C)C1CCCO1 Chemical compound CC(C)C1=CC=CC=N1.CC(C)C1=NC=CC=N1.CC(C)C1=[SH]C=NC1C.CC(C)C1CCCCC1.CC(C)C1CCCO1 VKSJFURIRILEFB-UHFFFAOYSA-N 0.000 description 2
- XTCBOTFCLGNYJY-UHFFFAOYSA-N CC(C)C1=CCCCC1.CC(C)C1CCCCC1.CC(C)C1CCCCCN1.CC(C)C1CCCCCO1.CC(C)C1CCOC1.CC(C)C1CS(=O)C1.CC(C)CCC1CCOC1.CC(C)N1C2COCC21.CC(C)N1CC(=O)C1.CC(C)N1CC2(COC2)C1.CC(C)N1CC2COCC2C1.CC(C)N1CC2OC2C1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCC1CO.CC(C)N1CCCCCC1.COC1CCN(C(C)C)C1 Chemical compound CC(C)C1=CCCCC1.CC(C)C1CCCCC1.CC(C)C1CCCCCN1.CC(C)C1CCCCCO1.CC(C)C1CCOC1.CC(C)C1CS(=O)C1.CC(C)CCC1CCOC1.CC(C)N1C2COCC21.CC(C)N1CC(=O)C1.CC(C)N1CC2(COC2)C1.CC(C)N1CC2COCC2C1.CC(C)N1CC2OC2C1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCC1CO.CC(C)N1CCCCCC1.COC1CCN(C(C)C)C1 XTCBOTFCLGNYJY-UHFFFAOYSA-N 0.000 description 2
- AABKYFQWOLKONK-UHFFFAOYSA-N CC(C)C1=NC=CC=N1.CC(C)C1=[SH]C=NC1C.CC(C)C1CCCCC1.CC(C)C1CCCO1 Chemical compound CC(C)C1=NC=CC=N1.CC(C)C1=[SH]C=NC1C.CC(C)C1CCCCC1.CC(C)C1CCCO1 AABKYFQWOLKONK-UHFFFAOYSA-N 0.000 description 2
- KXIXHISTUVHOCY-UHFFFAOYSA-N CC(C)N1CCCCC1 Chemical compound CC(C)N1CCCCC1 KXIXHISTUVHOCY-UHFFFAOYSA-N 0.000 description 2
- PDXXTWKFJGORQG-UHFFFAOYSA-N CC.CC.CC.CC(C)C1=NC=CS1.CC(C)C1=NNC=C1.CC(C)N1C=CC=N1 Chemical compound CC.CC.CC.CC(C)C1=NC=CS1.CC(C)C1=NNC=C1.CC(C)N1C=CC=N1 PDXXTWKFJGORQG-UHFFFAOYSA-N 0.000 description 2
- SHYGFNMAVAMQEQ-NILKIKDOSA-N CC1=CC=CC(C2=NN(C3=CC(C4CCOC4)=NC(OCC4CCCO4)=N3)C=C2)=C1.COCCS(=O)C1=NC(OCC2CCCO2)=NC(N2C=CC(C3=CC(C)=CC=C3)=N2)=C1.[H][C@@]12CCN(C3=NC(OCCC4=NC=CC=C4)=NC(N4C=CC(C5=CC(OC)=CC=C5)=N4)=C3)[C@]1([H])CCO2 Chemical compound CC1=CC=CC(C2=NN(C3=CC(C4CCOC4)=NC(OCC4CCCO4)=N3)C=C2)=C1.COCCS(=O)C1=NC(OCC2CCCO2)=NC(N2C=CC(C3=CC(C)=CC=C3)=N2)=C1.[H][C@@]12CCN(C3=NC(OCCC4=NC=CC=C4)=NC(N4C=CC(C5=CC(OC)=CC=C5)=N4)=C3)[C@]1([H])CCO2 SHYGFNMAVAMQEQ-NILKIKDOSA-N 0.000 description 2
- OHMLXCLNKJHINF-UHFFFAOYSA-N CC1=CC=CC(C2=NN(C3=CC(N4CCCOCC4)=NC(OCC4CCCO4)=N3)C=C2)=C1.CC1=CC=CC(N2C=CC(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)=N2)=C1.COC1CCN(C2=NC(OCC3CCCO3)=NC(N3C=CC(C4=CC(C)=CC=C4)=N3)=C2)C1 Chemical compound CC1=CC=CC(C2=NN(C3=CC(N4CCCOCC4)=NC(OCC4CCCO4)=N3)C=C2)=C1.CC1=CC=CC(N2C=CC(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)=N2)=C1.COC1CCN(C2=NC(OCC3CCCO3)=NC(N3C=CC(C4=CC(C)=CC=C4)=N3)=C2)C1 OHMLXCLNKJHINF-UHFFFAOYSA-N 0.000 description 2
- AUAOBMLTCDHPJI-HLUKFBSCSA-N CC1=CC=CC(C2=NN(C3=CC(N4CCOCC4CO)=NC(CCC4CCCO4)=N3)C=C2)=C1.[H][C@@]12CCN(C3=CC(N4C=CC(C5=CC(C)=CC=C5)=N4)=NC(CCC4=NC=CC=N4)=N3)[C@]1([H])CCO2 Chemical compound CC1=CC=CC(C2=NN(C3=CC(N4CCOCC4CO)=NC(CCC4CCCO4)=N3)C=C2)=C1.[H][C@@]12CCN(C3=CC(N4C=CC(C5=CC(C)=CC=C5)=N4)=NC(CCC4=NC=CC=N4)=N3)[C@]1([H])CCO2 AUAOBMLTCDHPJI-HLUKFBSCSA-N 0.000 description 2
- WRTQUPVPLJVQIF-HXHNPAONSA-N COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)C=C2)=CC=C1.COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCCC4CCOCC4)=N3)C=C2)=CC=C1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 Chemical compound COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)C=C2)=CC=C1.COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCCC4CCOCC4)=N3)C=C2)=CC=C1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 WRTQUPVPLJVQIF-HXHNPAONSA-N 0.000 description 2
- JPNFYPCPKVTCET-QNSPWMEWSA-N COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCCC(O)CO)=N3)C=C2)=CC=C1.COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCCC4=C(C)N=CS4)=N3)C=C2)=CC=C1.[H][C@@]12CCN(C3=NC(OCCC(O)CO)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 Chemical compound COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCCC(O)CO)=N3)C=C2)=CC=C1.COC1=CC(C2=NN(C3=CC(N4CCOCC4)=NC(OCCC4=C(C)N=CS4)=N3)C=C2)=CC=C1.[H][C@@]12CCN(C3=NC(OCCC(O)CO)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 JPNFYPCPKVTCET-QNSPWMEWSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- HZDVQUUNOLLJAO-PXBZQKCUSA-N [H][C@@]12CCN(C3=NC(OCCC4=C(C)N=CS4)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2.[H][C@@]12CCN(C3=NC(OCCC4=NC=CC=C4)=NC(N4C=CC(C5=CC=CC=C5)=N4)=C3)[C@]1([H])CCO2.[H][C@@]12CCN(C3=NC(OCCO)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 Chemical compound [H][C@@]12CCN(C3=NC(OCCC4=C(C)N=CS4)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2.[H][C@@]12CCN(C3=NC(OCCC4=NC=CC=C4)=NC(N4C=CC(C5=CC=CC=C5)=N4)=C3)[C@]1([H])CCO2.[H][C@@]12CCN(C3=NC(OCCO)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 HZDVQUUNOLLJAO-PXBZQKCUSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003413 dolasetron Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- 229960003727 granisetron Drugs 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 2
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 229960002131 palonosetron Drugs 0.000 description 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229940099039 velcade Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SSOZXXUSHMYCRH-PHDIDXHHSA-N (3aR,6aR)-3,3a,4,5,6,6a-hexahydro-2H-furo[3,2-b]pyrrole Chemical compound O1CC[C@H]2NCC[C@H]21 SSOZXXUSHMYCRH-PHDIDXHHSA-N 0.000 description 1
- UQANGIUGPBABBB-CEAUUGKZSA-N (3aR,6aR)-4-[6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound COC=1C=C(C=CC=1)C1=NN(C=C1)C1=CC(=NC(=N1)OCC1OCCC1)N1[C@H]2[C@@H](CC1)OCC2 UQANGIUGPBABBB-CEAUUGKZSA-N 0.000 description 1
- JWNPXNUVNZVIOS-PQDIPPBSSA-N (3aR,6aR)-4-[6-chloro-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrole Chemical compound ClC1=CC(=NC(=N1)OCC1OCCC1)N1[C@H]2[C@@H](CC1)OCC2 JWNPXNUVNZVIOS-PQDIPPBSSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical group CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KOWXKIHEBFTVRU-UHFFFAOYSA-N *.CC.CC Chemical compound *.CC.CC KOWXKIHEBFTVRU-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- YYEZYENJAMOWHW-UHFFFAOYSA-N 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol Chemical compound CC1(C)OCC(CCO)O1 YYEZYENJAMOWHW-UHFFFAOYSA-N 0.000 description 1
- KTBLRYUFNBABGO-UHFFFAOYSA-N 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=COC=C1 KTBLRYUFNBABGO-UHFFFAOYSA-N 0.000 description 1
- XZXZZACRGBBWTQ-UHFFFAOYSA-N 2-(oxan-4-yl)ethanol Chemical compound OCCC1CCOCC1 XZXZZACRGBBWTQ-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- BDLXTDLGTWNUFM-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxy]ethanol Chemical compound CC(C)(C)OCCO BDLXTDLGTWNUFM-UHFFFAOYSA-N 0.000 description 1
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- KIZQNNOULOCVDM-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].C[N+](C)(C)CCO KIZQNNOULOCVDM-UHFFFAOYSA-M 0.000 description 1
- VHXDADVHQVXSKC-UHFFFAOYSA-N 2-methoxyethanethiol Chemical compound COCCS VHXDADVHQVXSKC-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- SSOZXXUSHMYCRH-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-2h-furo[3,2-b]pyrrole Chemical compound O1CCC2NCCC21 SSOZXXUSHMYCRH-UHFFFAOYSA-N 0.000 description 1
- PRBBMELBFNBDOM-UHFFFAOYSA-N 4,6-dichloro-2-(2-pyridin-2-ylethoxy)pyrimidine Chemical compound ClC1=NC(=NC(=C1)Cl)OCCC1=NC=CC=C1 PRBBMELBFNBDOM-UHFFFAOYSA-N 0.000 description 1
- HOPDHXJDXWTWET-UHFFFAOYSA-N 4,6-dichloro-2-(2-pyrimidin-2-ylethyl)pyrimidine Chemical compound ClC1=NC(=NC(=C1)Cl)CCC1=NC=CC=N1 HOPDHXJDXWTWET-UHFFFAOYSA-N 0.000 description 1
- FCMLONIWOAGZJX-UHFFFAOYSA-N 4,6-dichloro-2-methylsulfanylpyrimidine Chemical compound CSC1=NC(Cl)=CC(Cl)=N1 FCMLONIWOAGZJX-UHFFFAOYSA-N 0.000 description 1
- GYHDZNARUILGIC-UHFFFAOYSA-N 4-(2-methoxyethylsulfanyl)-6-[3-(3-methylphenyl)pyrazol-1-yl]-2-(oxolan-2-ylmethoxy)pyrimidine Chemical compound COCCSC1=CC(=NC(OCC2CCCO2)=N1)N1C=CC(=N1)C1=CC(C)=CC=C1 GYHDZNARUILGIC-UHFFFAOYSA-N 0.000 description 1
- LOSTWTLWKZQLMQ-UHFFFAOYSA-N 4-(3-methoxypyrrolidin-1-yl)-6-[3-(3-methylphenyl)pyrazol-1-yl]-2-(oxolan-2-ylmethoxy)pyrimidine Chemical compound COC1CCN(C1)C1=CC(=NC(OCC2CCCO2)=N1)N1C=CC(=N1)C1=CC(C)=CC=C1 LOSTWTLWKZQLMQ-UHFFFAOYSA-N 0.000 description 1
- DTQQALVRFJPRTN-UHFFFAOYSA-N 4-(3-methylphenyl)-1,3-thiazole Chemical compound CC1=CC=CC(C=2N=CSC=2)=C1 DTQQALVRFJPRTN-UHFFFAOYSA-N 0.000 description 1
- JMEXGLULHZITFP-UHFFFAOYSA-N 4-[2-(3,5-dichlorophenoxy)ethyl]oxane Chemical compound ClC=1C=C(OCCC2CCOCC2)C=C(C=1)Cl JMEXGLULHZITFP-UHFFFAOYSA-N 0.000 description 1
- CGAFUUGUUUZEII-UHFFFAOYSA-N 4-[2-[2-(oxan-4-yl)ethoxy]-6-(3-phenylpyrazol-1-yl)pyrimidin-4-yl]morpholine Chemical compound C(CC1CCOCC1)OC1=NC(=CC(=N1)N1C=CC(=N1)C1=CC=CC=C1)N1CCOCC1 CGAFUUGUUUZEII-UHFFFAOYSA-N 0.000 description 1
- RESSLOTWOHGGNP-JNVGEPLTSA-N 4-[3-[(3aR,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrol-4-yl]-5-[3-(3-methoxyphenyl)pyrazol-1-yl]phenoxy]butane-1,2-diol Chemical compound COC1=CC=CC(=C1)C1=NN(C=C1)C1=CC(OCCC(O)CO)=CC(=C1)N1CC[C@H]2OCC[C@@H]12 RESSLOTWOHGGNP-JNVGEPLTSA-N 0.000 description 1
- WHXAOUWXVPAKMQ-UHFFFAOYSA-N 4-[6-[1-(3-methylphenyl)pyrazol-3-yl]-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]morpholine Chemical compound CC1=CC=CC(=C1)N1C=CC(=N1)C1=NC(OCC2CCCO2)=NC(=C1)N1CCOCC1 WHXAOUWXVPAKMQ-UHFFFAOYSA-N 0.000 description 1
- ZUWZROSJHVNCAA-UHFFFAOYSA-N 4-[6-[3-(3-methylphenyl)pyrazol-1-yl]-2-(oxolan-2-ylmethoxy)pyrimidin-4-yl]-1,4-oxazepane Chemical compound CC1=CC=CC(=C1)C1=NN(C=C1)C1=NC(OCC2CCCO2)=NC(=C1)N1CCCOCC1 ZUWZROSJHVNCAA-UHFFFAOYSA-N 0.000 description 1
- ZAFKFIJEZIUKLK-UHFFFAOYSA-N 4-chloro-6-(3-phenylpyrazol-1-yl)-2-(2-pyridin-2-ylethoxy)pyrimidine Chemical compound ClC1=NC(=NC(=C1)N1N=C(C=C1)C1=CC=CC=C1)OCCC1=NC=CC=C1 ZAFKFIJEZIUKLK-UHFFFAOYSA-N 0.000 description 1
- XLRQVIDHPVGLOZ-UHFFFAOYSA-N 4-chloro-6-[3-(3-methoxyphenyl)pyrazol-1-yl]-2-(2-pyridin-2-ylethoxy)pyrimidine Chemical compound ClC1=NC(=NC(=C1)N1N=C(C=C1)C1=CC(=CC=C1)OC)OCCC1=NC=CC=C1 XLRQVIDHPVGLOZ-UHFFFAOYSA-N 0.000 description 1
- BYOGXHMTSJRLHJ-UHFFFAOYSA-N 4-chloro-6-[3-(3-methylphenyl)pyrazol-1-yl]-2-[2-(oxolan-2-yl)ethyl]pyrimidine Chemical compound ClC1=NC(=NC(=C1)N1N=C(C=C1)C=1C=C(C=CC=1)C)CCC1OCCC1 BYOGXHMTSJRLHJ-UHFFFAOYSA-N 0.000 description 1
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 description 1
- KWLOIDOKWUESNM-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1 KWLOIDOKWUESNM-UHFFFAOYSA-N 0.000 description 1
- XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1h-imidazole Chemical compound N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 description 1
- YBPIBGNBHHGLEB-UHFFFAOYSA-N 6-amino-N-[3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenyl]-3-pyridinecarboxamide Chemical compound C1=NC(N)=CC=C1C(=O)NC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 YBPIBGNBHHGLEB-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- YVRJWZDLZWLXNV-UHFFFAOYSA-N C.C1=CC(C2=CC(N3CCOCC3)=NC(OCC3CCCO3)=N2)=NN1.CC1(C)OB(C2=CC=NC2)OC1(C)C.CC1=CC=CC(Br)=C1.CC1=CC=CC(N2C=CC(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)=N2)=C1 Chemical compound C.C1=CC(C2=CC(N3CCOCC3)=NC(OCC3CCCO3)=N2)=NN1.CC1(C)OB(C2=CC=NC2)OC1(C)C.CC1=CC=CC(Br)=C1.CC1=CC=CC(N2C=CC(C3=CC(N4CCOCC4)=NC(OCC4CCCO4)=N3)=N2)=C1 YVRJWZDLZWLXNV-UHFFFAOYSA-N 0.000 description 1
- IUBMKLRHFOHIJL-XNPDZEALSA-N C1=CC=C(C2=CN(C3=CC(N4CCOCC4)=NC(OCCC4=NC=CC=C4)=N3)C=N2)C=C1.C1=CC=C(C2=CN=CC2)C=C1.C1CCOCC1.[2H]C(=O)OOC(F)([Cs])[Cs] Chemical compound C1=CC=C(C2=CN(C3=CC(N4CCOCC4)=NC(OCCC4=NC=CC=C4)=N3)C=N2)C=C1.C1=CC=C(C2=CN=CC2)C=C1.C1CCOCC1.[2H]C(=O)OOC(F)([Cs])[Cs] IUBMKLRHFOHIJL-XNPDZEALSA-N 0.000 description 1
- YWCYIIAOHKGBMM-UHFFFAOYSA-M C1=CC=C(C2=NNC=C2)C=C1.C1=COC=C1.C1CO1.CC(C)[Mg]Br.CC1=CC=CC(C2=NN(C3=CC(Cl)=NC(CCC4CCCO4)=N3)C=C2)=C1.CCCC1CCCO1.ClC1=CC(Cl)=NC(CCC2CCCO2)=N1.ICCC1CCCO1.OCCC1=CC=CO1.OCCC1CCCO1 Chemical compound C1=CC=C(C2=NNC=C2)C=C1.C1=COC=C1.C1CO1.CC(C)[Mg]Br.CC1=CC=CC(C2=NN(C3=CC(Cl)=NC(CCC4CCCO4)=N3)C=C2)=C1.CCCC1CCCO1.ClC1=CC(Cl)=NC(CCC2CCCO2)=N1.ICCC1CCCO1.OCCC1=CC=CO1.OCCC1CCCO1 YWCYIIAOHKGBMM-UHFFFAOYSA-M 0.000 description 1
- BIQYGWDCWDIHEG-KHHOBTSVSA-P C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CC1=CC=CC(C2=CSC(Br)=N2)=C1.CC1=CC=CC(C2=CSC=N2)=C1.CCCC[Sn](CCCC)(CCCC)(CCCC)(CCCC)(CCCC)[Sn]([Pd])([PH](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)[PH](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(C4=NC(C5=CC(C)=CC=C5)=CS4)=C3)[C@]1([H])CCO2 Chemical compound C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.CC1=CC=CC(C2=CSC(Br)=N2)=C1.CC1=CC=CC(C2=CSC=N2)=C1.CCCC[Sn](CCCC)(CCCC)(CCCC)(CCCC)(CCCC)[Sn]([Pd])([PH](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)[PH](C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(C4=NC(C5=CC(C)=CC=C5)=CS4)=C3)[C@]1([H])CCO2 BIQYGWDCWDIHEG-KHHOBTSVSA-P 0.000 description 1
- RABVHHACQVGJPC-UHFFFAOYSA-N C1CCOC1.ClC1=CC(Cl)=NC(OCCC2=NC=CC=C2)=N1.OCCC1=CC=CC=N1.[NaH] Chemical compound C1CCOC1.ClC1=CC(Cl)=NC(OCCC2=NC=CC=C2)=N1.OCCC1=CC=CC=N1.[NaH] RABVHHACQVGJPC-UHFFFAOYSA-N 0.000 description 1
- SKSNXSWDXSVSDX-UHFFFAOYSA-N C1CCOCC1.ClC1=CC(N2CCOCC2)=NC(OCC2CCCO2)=N1.OCC1CCCO1 Chemical compound C1CCOCC1.ClC1=CC(N2CCOCC2)=NC(OCC2CCCO2)=N1.OCC1CCCO1 SKSNXSWDXSVSDX-UHFFFAOYSA-N 0.000 description 1
- JHTYMRTZKTWMNK-UHFFFAOYSA-N C1CNCCOC1.CC1=CC=CC(C2=NN(C3=CC(N4CCCOCC4)=NC(OCC4CCCO4)=N3)C=C2)=C1.Cl Chemical compound C1CNCCOC1.CC1=CC=CC(C2=NN(C3=CC(N4CCCOCC4)=NC(OCC4CCCO4)=N3)C=C2)=C1.Cl JHTYMRTZKTWMNK-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 102000043334 C9orf72 Human genes 0.000 description 1
- 108700030955 C9orf72 Proteins 0.000 description 1
- ULZDWBRNTNWUPX-UHFFFAOYSA-N CC(C)C1=CCCCC1.CC(C)C1CCCCC1.CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCC1CO.CC(C)N1CCCCCC1.COC1CCN(C(C)C)C1 Chemical compound CC(C)C1=CCCCC1.CC(C)C1CCCCC1.CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCC1CO.CC(C)N1CCCCCC1.COC1CCN(C(C)C)C1 ULZDWBRNTNWUPX-UHFFFAOYSA-N 0.000 description 1
- HSXHOIUJPDYEIC-UHFFFAOYSA-N CC(C)C1=CCCCC1.CC(C)C1CCCCC1.CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCCC1.CC(C)N1CCOCC1CO.COC1CCN(C(C)C)C1 Chemical compound CC(C)C1=CCCCC1.CC(C)C1CCCCC1.CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCCC1.CC(C)N1CCOCC1CO.COC1CCN(C(C)C)C1 HSXHOIUJPDYEIC-UHFFFAOYSA-N 0.000 description 1
- YEJIKLJRUCRTBB-UHFFFAOYSA-N CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCC1CO Chemical compound CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCCCC1CO YEJIKLJRUCRTBB-UHFFFAOYSA-N 0.000 description 1
- PINKZYVPALDBDE-UHFFFAOYSA-N CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCOCC1CO Chemical compound CC(C)C1CCOC1.CC(C)N1CCC2OCCC21.CC(C)N1CCCCC1.CC(C)N1CCOCC1CO PINKZYVPALDBDE-UHFFFAOYSA-N 0.000 description 1
- LXSORXCOKVCCDN-UHFFFAOYSA-N CC1(C)OB(C2C=CO=C2)OC1(C)C.CC1=CC=CC(C2=NN(C3=CC(C4=COC=C4)=NC(OCC4CCCO4)=N3)C=C2)=C1.CC1=CC=CC(C2=NN(C3=CC(C4CCOC4)=NC(OCC4CCCO4)=N3)C=C2)=C1 Chemical compound CC1(C)OB(C2C=CO=C2)OC1(C)C.CC1=CC=CC(C2=NN(C3=CC(C4=COC=C4)=NC(OCC4CCCO4)=N3)C=C2)=C1.CC1=CC=CC(C2=NN(C3=CC(C4CCOC4)=NC(OCC4CCCO4)=N3)C=C2)=C1 LXSORXCOKVCCDN-UHFFFAOYSA-N 0.000 description 1
- RQKOCHQRXACAFX-UHFFFAOYSA-N CC1(C)OB(C2C=[O]C=C2)OC1(C)C Chemical compound CC1(C)OB(C2C=[O]C=C2)OC1(C)C RQKOCHQRXACAFX-UHFFFAOYSA-N 0.000 description 1
- RDYNARGCTLXIDU-MCXNCHQQSA-N CC1(C)OCC(CCO)O1.CC1(C)OCC(CCOC2=NC(Cl)=CC(Cl)=N2)O1.COC1=CC=CC(C2=NN(C3=CC(Cl)=NC(OCCC4COC(C)(C)O4)=N3)C=C2)=C1.COC1=CC=CC(C2=NNC=C2)=C1.[H][C@@]12CCN(C3=NC(OCCC(O)CO)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 Chemical compound CC1(C)OCC(CCO)O1.CC1(C)OCC(CCOC2=NC(Cl)=CC(Cl)=N2)O1.COC1=CC=CC(C2=NN(C3=CC(Cl)=NC(OCCC4COC(C)(C)O4)=N3)C=C2)=C1.COC1=CC=CC(C2=NNC=C2)=C1.[H][C@@]12CCN(C3=NC(OCCC(O)CO)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 RDYNARGCTLXIDU-MCXNCHQQSA-N 0.000 description 1
- SGOFLQCUEVSWMO-UHFFFAOYSA-N CC1=CC=CC(C2=NN(C3=CC(N4CCOCC4CO)=NC(CCC4CCCO4)=N3)C=C2)=C1.OCC1COCCN1 Chemical compound CC1=CC=CC(C2=NN(C3=CC(N4CCOCC4CO)=NC(CCC4CCCO4)=N3)C=C2)=C1.OCC1COCCN1 SGOFLQCUEVSWMO-UHFFFAOYSA-N 0.000 description 1
- AKVYODZJWVXEPA-XZHZQXPNSA-N CC1=CC=CC(C2=NNC=C2)=C1.ClC1=CC(Cl)=NC(CCC2=NC=CC=N2)=N1.[H][C@@]12CCN(C3=CC(N4C=CC(C5=CC(C)=CC=C5)=N4)=NC(CCC4=NC=CC=N4)=N3)[C@]1([H])CCO2 Chemical compound CC1=CC=CC(C2=NNC=C2)=C1.ClC1=CC(Cl)=NC(CCC2=NC=CC=N2)=N1.[H][C@@]12CCN(C3=CC(N4C=CC(C5=CC(C)=CC=C5)=N4)=NC(CCC4=NC=CC=N4)=N3)[C@]1([H])CCO2 AKVYODZJWVXEPA-XZHZQXPNSA-N 0.000 description 1
- QRBYOOCJZHBHNX-FKDPVRQZSA-N COC1=CC=CC(C2=CC=NC2)=C1.ClC1=CC(Cl)=NC(OCC2CCCO2)=N1.OCC1CCCO1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 Chemical compound COC1=CC=CC(C2=CC=NC2)=C1.ClC1=CC(Cl)=NC(OCC2CCCO2)=N1.OCC1CCCO1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(N4C=CC(C5=CC=CC(OC)=C5)=N4)=C3)[C@]1([H])CCO2 QRBYOOCJZHBHNX-FKDPVRQZSA-N 0.000 description 1
- IUEMVEKYDRLDJW-UHFFFAOYSA-N COC1=CC=CC(C2=NCC=C2)=C1.COC1=CC=CC(C2=NN(C3=CC(Cl)=NC(OCCC4=NC=CC=C4)=N3)C=C2)=C1 Chemical compound COC1=CC=CC(C2=NCC=C2)=C1.COC1=CC=CC(C2=NN(C3=CC(Cl)=NC(OCCC4=NC=CC=C4)=N3)C=C2)=C1 IUEMVEKYDRLDJW-UHFFFAOYSA-N 0.000 description 1
- LRJWUMLUNLTNFC-UHFFFAOYSA-N COC1CCN(C2=NC(OCC3CCCC3)=NC(N3C=CC(C4=CC(C)=CC=C4)=N3)=C2)C1.COC1CCNC1 Chemical compound COC1CCN(C2=NC(OCC3CCCC3)=NC(N3C=CC(C4=CC(C)=CC=C4)=N3)=C2)C1.COC1CCNC1 LRJWUMLUNLTNFC-UHFFFAOYSA-N 0.000 description 1
- ZPMSGCDDGVQJRG-UHFFFAOYSA-N COCCS.COCCS(=O)C1=NC(OCC2CCCO2)=NC(N2C=CC(C3=CC(C)=CC=C3)=N2)=C1.COCCSC1=NC(OCC2CCCO2)=NC(N2C=CC(C3=CC(C)=CC=C3)=N2)=C1 Chemical compound COCCS.COCCS(=O)C1=NC(OCC2CCCO2)=NC(N2C=CC(C3=CC(C)=CC=C3)=N2)=C1.COCCSC1=NC(OCC2CCCO2)=NC(N2C=CC(C3=CC(C)=CC=C3)=N2)=C1 ZPMSGCDDGVQJRG-UHFFFAOYSA-N 0.000 description 1
- YWJSIVDRRNUGGF-UHFFFAOYSA-N CS(=O)(=O)C1=NC(Cl)=CC(Cl)=N1.CSC1=NC(Cl)=CC(Cl)=N1 Chemical compound CS(=O)(=O)C1=NC(Cl)=CC(Cl)=N1.CSC1=NC(Cl)=CC(Cl)=N1 YWJSIVDRRNUGGF-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- DBNBOHSZQXNIBG-UHFFFAOYSA-N Cc1cccc(-c(cc2)n[n]2-c2cc(-c3c[o]cc3)nc(OCC3OCCC3)n2)c1 Chemical compound Cc1cccc(-c(cc2)n[n]2-c2cc(-c3c[o]cc3)nc(OCC3OCCC3)n2)c1 DBNBOHSZQXNIBG-UHFFFAOYSA-N 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000016403 Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000021252 FYVE-type zinc finger Human genes 0.000 description 1
- 108091011169 FYVE-type zinc finger Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CSTBCDQZGDEJDJ-ILRKGUEASA-N OCC1CCCO1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(Cl)=C3)[C@]1([H])CCO2 Chemical compound OCC1CCCO1.[H][C@@]12CCN(C3=NC(OCC4CCCO4)=NC(Cl)=C3)[C@]1([H])CCO2 CSTBCDQZGDEJDJ-ILRKGUEASA-N 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000023582 Primary cutaneous diffuse large B-cell lymphoma, leg type Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- UZMPYXSDDZXMAI-OHKKONBVSA-N [(2r)-2-hexadecanoyloxy-3-[hydroxy-[(2r,3r,5s,6r)-2,4,6-trihydroxy-3,5-diphosphonooxycyclohexyl]oxyphosphoryl]oxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@@H](OP(O)(O)=O)C(O)[C@@H](OP(O)(O)=O)[C@H]1O UZMPYXSDDZXMAI-OHKKONBVSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- GBXXKLFAZKNDCU-UHFFFAOYSA-N [4-[6-[3-(3-methylphenyl)pyrazol-1-yl]-2-[2-(oxolan-2-yl)ethyl]pyrimidin-4-yl]morpholin-3-yl]methanol Chemical compound CC1=CC=CC(=C1)C1=NN(C=C1)C1=NC(CCC2CCCO2)=NC(=C1)N1CCOCC1CO GBXXKLFAZKNDCU-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 1
- 229960002402 cobicistat Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LSSJUKDVBOYWHG-UHFFFAOYSA-N ethyl 2-azidopropanoate Chemical compound CCOC(=O)C(C)N=[N+]=[N-] LSSJUKDVBOYWHG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- BMQVDVJKPMGHDO-UHFFFAOYSA-K magnesium;potassium;chloride;sulfate;trihydrate Chemical compound O.O.O.[Mg+2].[Cl-].[K+].[O-]S([O-])(=O)=O BMQVDVJKPMGHDO-UHFFFAOYSA-K 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UCDFBOLUCCNTDQ-UHFFFAOYSA-N morpholin-3-ylmethanol Chemical compound OCC1COCCN1 UCDFBOLUCCNTDQ-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- WNYIBZHOMJZDKN-UHFFFAOYSA-N n-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 description 1
- RFZQYGBLRIKROZ-PCLIKHOPSA-N n-[(e)-(3-methylphenyl)methylideneamino]-7-morpholin-4-yl-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-5-amine Chemical compound CC1=CC=CC(\C=N\NC2=NC3=CC(=NN3C(N3CCOCC3)=C2)C=2C=CN=CC=2)=C1 RFZQYGBLRIKROZ-PCLIKHOPSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve).
- PIKfyve phosphatidylinositol-3-phosphate 5-kinase
- IL-12 and IL-23 are inflammatory cytokines normally produced by immune cells, such as B-cells and macrophages, in response to antigenic stimulation. Autoimmune disorders and other disorders characterized by chronic inflammation are characterized in part by inappropriate production of these cytokines.
- apilimod the selective inhibition of IL-12/IL-23 transcription by apilimod was recently shown to be mediated by apilimod's direct binding to phosphatidylinositol-3-phosphate 5-kinase (PIKfyve). See Cai et al., Chemistry and Biol. 20 (2013):912-921. PIKfyve plays a role in Toll-like receptor signaling, which is important in innate immunity.
- apilimod Based upon its activity as an immunomodulatory agent and a specific inhibitor of IL-12/IL-23, apilimod has been proposed as useful in treating autoimmune and inflammatory diseases and disorders. See U.S. Pat. Nos. 6,858,606 and 6,660,733 (describing a family of pyrimidine compounds, including apilimod, purportedly useful for treating diseases and disorders characterized by IL-12 or IL-23 overproduction, such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin dependent diabetes mellitus).
- apilimod was suggested to be useful for treating certain cancers based upon its activity to inhibit c-Rel or IL-12/23, particularly in cancers where these cytokines were believed to play a role in promoting aberrant cell proliferation.
- International Publication No. WO 2016/210372 and U.S. Patent Publication No. 2018/0161335 disclose methods of treating a neurological disease such as amyotrophic lateral sclerosis with a PIKFYVE kinase inhibitor.
- the present invention is directed to a compound of the formula (I)
- R 1 is hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- each occurrence of R 2 is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- R 3 is a nitrogen- or oxygen-containing moiety
- Ring A is (i) a 5 or 6-membered heteroaryl or 5-6 or 6-5 membered bicyclic heteroaryl, each having at least one nitrogen or oxygen ring atom, or (ii) phenyl;
- L 1 is absent, C 1 -C 2 alkylene, —NR c —, —O—, —S—, —C(O)—, —NHC(O)—, or —C(O)NH—;
- L 2 is —O—(CR a R b ) m —, —(CR a R b ) m —, —NR c —(CR a R b ) m —, or —S—(CR a R b ) m —;
- X 1 is CH, N, or CR c ;
- each occurrence of R a and R b are independently hydrogen, hydroxy, hydroxy(C 1-4 )alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl, halogen, nitro, —OR d , —SR d , —NR d R e , —C(O)R d , —C(S)R d , —OC(O)R d , —SC(O)R d , OC(S)R d , SC(S)R d , —NR c C(O)R d , —NR
- R c is a hydrogen or C 1-6 alkyl (e.g., C 1 -C 4 alkyl);
- each occurrence of R d and R e are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- n 1-4;
- p 1 or 2.
- These compounds are useful as PIKfyve kinase inhibitors.
- R 1 is heterocyclyl or heteroaryl.
- R 1 may be selected from (the squiggly lines indicate the point of attached to the rest of the molecule)
- R 1 is hydroxy
- each occurrence of R 2 is independently substituted or unsubstituted aryl, such as a substituted or unsubstituted phenyl.
- R 2 may be phenyl, a halogen-substituted phenyl, an alkyl-substituted phenyl (e.g., a C 1-4 alkyl-substituted phenyl), a halogenated alkyl-substituted phenyl, or an alkoxy-substituted phenyl.
- R 2 is selected from phenyl, 3-methoxyphenyl, 3-methylphenyl, 3-trifluoromethylphenyl, and 3-chlorophenyl. In a preferred embodiment, R 2 is selected from phenyl, 3-methoxyphenyl, and 3-methylphenyl.
- each occurrence of R 2 is independently substituted or unsubstituted alkyl (such as a C 1-4 alkyl).
- R 2 can be unsubstituted isopropyl.
- R 3 is a substituted or unsubstituted, saturated or unsaturated nitrogen- or oxygen-containing heterocyclyl.
- R 3 can be a substituted or unsubstituted, saturated or unsaturated 5-10 membered (such as a 5-8 membered) mono- or bi-cyclic heterocyclyl having at least one nitrogen or oxygen ring atom.
- R 3 is a substituted or unsubstituted 5-10 membered (such as a 5-8 membered) mono- or bi-cyclic heterocyclyl having at least one nitrogen atom and optionally an oxygen ring atom, where the nitrogen ring atom is directly attached to the rest of the molecule.
- R 3 is a substituted or unsubstituted (unsaturated) 5-membered monocyclic heterocyclyl having an oxygen ring atom or a nitrogen ring atom.
- R 3 is a substituted or unsubstituted, saturated or unsaturated 6-membered monocyclic heterocyclyl having an oxygen ring atom and optionally a nitrogen ring atom.
- R 3 is a saturated 8-membered bicyclic heterocyclyl having a nitrogen ring atom and an oxygen ring atom.
- R 3 is selected from
- R 3 is selected from
- R 3 is
- R 3 is a sulfonyl group of the formula —S(O)(CH 2 ) q OR 4 , where R 4 is hydrogen or C 1 -C 4 alkyl and q is 1-4.
- ring A is a 5-membered heteroaryl having at least one nitrogen ring atom.
- ring A includes two heteroatoms as ring atoms (such as two nitrogen ring atoms, or one nitrogen ring atom with one sulfur ring atom).
- ring A is selected from
- ring A can be selected from
- the R 2 group in ring A above is selected from substituted or unsubstituted aryl, such as a substituted or unsubstituted phenyl.
- R 2 may be phenyl, an alkyl-substituted, or an alkoxy-substituted phenyl.
- R 2 is selected from phenyl, 3-methoxyphenyl, and 3-methylphenyl.
- L 1 is absent.
- L 1 is —NH—, —N(CH 3 )—, —O—, or —CH 2 —.
- L 1 is —NH—.
- L 1 is —C(O)NH— (where the carbonyl is attached to the rest of the molecule and the nitrogen is attached to ring A).
- L 1 is —NHC(O)— (where the nitrogen atom is attached to the rest of the molecule and the carbonyl is attached to ring A).
- L 2 is —O—(CR a R b ) m —. In one preferred embodiment, L 2 is —OCH 2 CH 2 — or —OCH 2 —. In another embodiment, L 2 is —OCH 2 CH 2 CH(OH)CH 2 —.
- L 2 is —(CR a R b ) m —. In one preferred embodiment, L 2 is —CH 2 CH 2 —.
- L 2 is —NR c —(CR a R b ) m —, such as —NH—(CR a R b ) m — (e.g., —NH—, —NHCH 2 —, and —NHCH 2 CH 2 —).
- -L 2 -R 1 is —OCH 2 CH 2 CH(OH)CH 2 OH.
- X 1 is CH. In another embodiment, X 1 is N.
- each occurrence of R a and R b are independently hydrogen, hydroxy, or hydroxy(C 1-4 )alkyl. In another embodiment, each occurrence of R a and R b are independently hydrogen or hydroxy.
- m is 1. In another embodiment, m is 2. In a preferred embodiment, m is 1 or 2 when R 1 is cyclic. In another preferred embodiment, m is 3 or 4 when R 1 is acyclic.
- p is 1.
- p is 2.
- the moiety is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl moiety
- Another embodiment is a compound of the formula (II)
- R 1 is hydroxy, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;
- R 2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- R 3 is a substituted or unsubstituted oxygen-containing heterocyclyl
- Ring A is a 5-membered heteroaryl having at least one nitrogen ring atom
- L 2 is —O—(CR a R b ) m —;
- each occurrence of R a and R b are independently hydrogen, hydroxy, or hydroxy(C 1-4 )alkyl
- n 1-4.
- R 1 is heterocyclyl or heteroaryl.
- R 1 may be selected from
- R 2 is substituted phenyl, such as an alkoxy-substituted phenyl, halogen-substituted phenyl, or alkyl-substituted phenyl.
- R 2 can be methoxyphenyl (e.g., 3-methoxyphenyl) or methylphenyl (e.g., 3-methylphenyl).
- R 2 is hydroxy
- R 3 is selected from
- R 3 is
- R 3 is
- ring A is a 5-membered heteroaryl having (i) two nitrogen ring atoms or (ii) one nitrogen ring atom and one sulfur ring atom. In another embodiment, ring A is selected from
- L 2 is —OCH 2 —, —OCH 2 CH 2 —, —OCH 2 CH 2 CH(OH)CH 2 —, or —CH 2 CH 2 —. In one preferred embodiment, L 2 is —OCH 2 —, —OCH 2 CH 2 —, or —OCH 2 CH 2 CH(OH)CH 2 —.
- Exemplary compounds of the present include those listed below and pharmaceutically salts thereof.
- Another embodiment is a method of inhibiting PIKfyve in a subject (such as a human subject) in need thereof comprising administering an effective amount of a compound of the present invention.
- Yet another embodiment is a method for treating a disease or disorder associated with PIKfyve in a human subject in need thereof comprising administering an effective amount of a compound of the present invention to the subject.
- Yet another embodiment is a method of treating a subject having a neurological disease comprising administering to the subject an effective amount of a compound of the present invention to the subject.
- the neurological disease is amyotrophic lateral sclerosis (ALS).
- the neurological disease is frontotemporal dementia (FTD).
- FTD frontotemporal dementia
- the neurological disease is Alzheimer's disease.
- the neurological disease is Parkinson's disease.
- the neurological disease is Huntington's disease.
- the neurological disease is Charcot-Marie-Tooth disease (CMT).
- the effective amount of the compound is the amount effective to inhibit cellular PIKfyve activity in target cells in the subject. In another embodiment, the effective amount is the amount effective to induce vacuolization and disrupts intracellular trafficking in target cells.
- the target cell is a cancer cell.
- the cancer cell is a lymphoma cell.
- the lymphoma cell is a non-Hodgkin's lymphoma cell.
- the disease of disorder is selected from a cancer, a viral infection, or a cell proliferative disorder.
- the cancer can be a lymphoma or melanoma.
- the cancer is refractory or resistant to standard therapy.
- the cancer is a non-Hodgkin's lymphoma.
- the viral infection can be caused by any type of virus such as RNA and DNA viruses.
- the virus is Ebola virus.
- the virus is middle east respiratory syndrome virus (MERS).
- the virus is JC polyomavirus (JC).
- the virus is BK polyomavirus (BK).
- the virus is Herpes Simplex Virus (HSV).
- HSV Herpes Simplex Virus
- the virus is Marburg virus (MarV).
- the virus is Venezuelan equine encephalitis virus (VEEV).
- the virus is Lymphocytic choriomeningitis virus (LCMV).
- Another embodiment is method of treating Charcot-Marie-Tooth disease (CMT) in a subject, preferably a human subject, in need of such treatment, by administering an effective amount of a compound of the present invention to the subject.
- CMT Charcot-Marie-Tooth disease
- One embodiment is a method for treating a lymphoma comprising administering (e.g., an effective amount of) a compound of the present invention and at least one additional active agent.
- the at least one additional active agent is selected from ibrutinib, rituximab, doxorubicin, prednisolone, vincristine, velcade, and everolimus, and combinations thereof.
- the method includes a therapeutic regimen comprising administering a compound of the present invention and a CHOP regimen.
- the method is a method for treating melanoma and the method further comprises administering at least one additional active agent to the subject in a therapeutic regimen comprising a compound of the present invention and the at least one additional active agent.
- the at least one additional active agent is selected from dacarbazine, temozolomide, Nab-paclitaxel, carmustine, cisplatin, carboplatin, or vinblastine.
- the method is a method for treating a viral infection and the method further comprises administering at least one additional active agent to the subject in a therapeutic regimen comprising a compound of the present invention and the at least one additional active agent.
- the at least one additional active agent is selected from selected from the group consisting of apilimod, APY0201, and YM-201636.
- a compound of the present invention may also be administered in combination with a non-therapeutic agent which mitigates one or more side effects associated with the compound or increases the bioavailability of the compound.
- the non-therapeutic agent is selected from the group consisting of ondansetron, granisetron, dolasetron and palonosetron.
- the non-therapeutic agent is selected from the group consisting of pindolol and risperidone.
- the non-therapeutic agent is selected from a cytochrome P450 3A (CYP3A) inhibitor.
- the CYP3A inhibitor is selected from ritonavir and cobicistat.
- the viral infection is caused by a virus selected from the group consisting of measles, Ebola (EboV), Marburg (MarV), borna disease, and human immunodeficiency virus (HIV), severe acute respiratory system virus (SARS), and middle east respiratory syndrome virus (MERS).
- the viral infection is caused by an EboV virus.
- the compound is in the form a pharmaceutical composition comprising the compound and at least one pharmaceutically acceptable carrier.
- the compound comprises at least 95% or at least 99% enantiomeric excess of the (R)-enantiomer. In one embodiment, the compound comprises at least 95% or at least 99% enantiomeric excess of the (S)-enantiomer.
- compositions comprising a compound of the present invention wherein the compound comprises at least 95% or at least 99% enantiomeric excess of the (R)-enantiomer or the (S)-enantiomer.
- alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl).
- C 1-6 alkyl refers to an alkyl group as defined above having up to 6 carbon atoms.
- C 1-3 alkyl refers to an alkyl group as defined above having up to 3 carbon atoms.
- the term “alkyl” refers to a hydrocarbon chain radical as mentioned above which is bivalent.
- alkenyl refers to an aliphatic hydrocarbon group containing one or more carbon-carbon double bonds and which may be a straight or branched or branched chain having about 2 to about 10 carbon atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, and 2-butenyl.
- C 2-6 alkenyl refers to an alkenyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term “alkenyl” refers to a hydrocarbon group as mentioned above which is bivalent.
- alkynyl refers to a straight or branched chain hydrocarbyl radical having at least one carbon-carbon triple bond, and having in the range of 2 to up to 12 carbon atoms (with radicals having in the range of 2 to up to 10 carbon atoms presently being preferred) e.g., ethynyl, propynyl, and butnyl.
- C 2-6 alkynyl refers to an alkynyl group as defined above having up to 6 carbon atoms.
- alkynyl refers to a hydrocarbyl radical as mentioned above which is bivalent.
- alkoxy unless otherwise specified, denotes an alkyl, cycloalkyl, or cycloalkylalkyl group as defined above attached via an oxygen linkage to the rest of the molecule.
- substituted alkoxy refers to an alkoxy group where the alkyl constituent is substituted (i.e., -0-(substituted alkyl).
- alkoxy refers to the group —O-alkyl, including from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and cyclohexyloxy.
- alkoxy refers to a group as mentioned above which is bivalent.
- cycloalkyl denotes a non-aromatic mono or multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- multicyclic cycloalkyl groups include perhydronaphthyl, adamantyl and norbornyl groups, bridged cyclic groups, and sprirobicyclic groups, e.g., sprio (4,4) non-2-yl.
- C 3-6 cycloalkyl refers to a cycloalkyl group as defined above having up to 6 carbon atoms.
- cycloalkylalkyl refers to a cyclic ring-containing radical containing in the range of about 3 up to 8 carbon atoms directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group, such as cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl.
- cycloalkenyl refers to cyclic ring-containing radicals containing in the range of about 3 up to 8 carbon atoms with at least one carbon-carbon double bond such as cyclopropenyl, cyclobutenyl, and cyclopentenyl.
- cycloalkenylalkyl refers to a cycloalkenyl group directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group.
- aryl refers to aromatic radicals having in the range of 6 up to 20 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl.
- arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., —CH 2 C 6 H 5 and —C 2 H 5 C 6 H 5 .
- heterocyclic ring refers to a non-aromatic 3 to 15 member ring radical which consists of carbon atoms and at least one heteroatom selected from nitrogen, phosphorus, oxygen and sulfur.
- the heterocyclic ring radical may be a mono-, bi-, tri- or tetracyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
- the nitrogen atom may be optionally quaternized.
- the heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom.
- heterocyclyl refers to a heterocylic ring radical as defined above.
- the heterocylcyl ring radical may be attached to the main structure at any heteroatom or carbon ring atom.
- heterocyclyl refers to a hydrocarbon chain radical as mentioned above which is bivalent.
- heterocyclylalkyl refers to a heterocylic ring radical as defined above directly bonded to an alkyl group.
- the heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group.
- heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-o-
- heteroaryl refers to an optionally substituted 5 to 14 member aromatic ring having one or more heteroatoms selected from N, O, and S as ring atoms.
- the heteroaryl may be a mono-, bi- or tricyclic ring system.
- heteroaryl radicals include, but are not limited to, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, carbazolyl, quinolyl, isoquinolyl, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxal
- the term “5 or 6-membered heteroaryl” refers to a heteroaryl having 5- or 6-ring atoms.
- the term “5-6 or 6-5 membered bicyclic heteroaryl” refers to a bicyclic heteroaryl with a five-membered ring fused to a six-membered ring, where the 5-membered ring is bound to the rest of the molecule (referred as a “5-6 membered bicyclic heteroaryl”) or the 6-membered ring is bound to the rest of the molecule (referred as a “6-5 membered bicyclic heteroaryl”).
- heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom.
- substituted heteroaryl also includes ring systems substituted with one or more oxide (—O—) substituents, such as pyridinyl N-oxides.
- heteroarylalkyl refers to a heteroaryl ring radical as defined above directly bonded to an alkyl group.
- the heteroarylalkyl radical may be attached to the main structure at any carbon atom from alkyl group.
- substituted refers to substitution with any one or any combination of the following substituents which may be the same or different and are independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo ( ⁇ O), thio ( ⁇ S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
- Substitution or the combinations of substituents envisioned by this invention are preferably those that result in the formation of a stable or chemically feasible compound.
- stable refers to the compounds or the structure that are not substantially altered when subjected to conditions to allow for their production, detection and preferably their recovery, purification and incorporation into a pharmaceutical composition.
- the substituents in the aforementioned “substituted” groups cannot be further substituted. For example, when the substituent on “substituted alkyl” is “substituted aryl”, the substituent on “substituted aryl” cannot be “substituted alkenyl”.
- halo means fluoro, chloro, bromo or iodo.
- haloalkyl haloalkenyl
- haloalkynyl haloalkoxy
- fluoroalkyl and fluoroalkoxy include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
- protecting group refers to a substituent that is employed to block or protect a particular functionality. Other functional groups on the compound may remain reactive.
- an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
- a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality.
- Suitable hydroxy-protecting groups include, but are not limited to, acetyl and silyl.
- a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality.
- Suitable carboxy-protecting groups include, but are not limited to, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, and nitroethyl.
- Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
- Non-limiting examples of intermediate mixtures include a mixture of isomers in a ratio of 10:90, 13:87, 17:83, 20:80, or 22:78.
- Optically active (R)- and (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
- a “leaving group or atom” is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms and mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.
- prodrug refers to a compound, which is an inactive precursor of a compound, converted into its active form in the body by normal metabolic processes. Prodrug design is discussed generally in Hardma, et al. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A thorough discussion is provided in Higuchi, et al., Prodrugs as Novel Delivery Systems, Vol. 14, ASCD Symposium Series, and in Roche (ed.), Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
- prodrugs can be converted into a pharmacologically active form through hydrolysis of, for example, an ester or amide linkage, thereby introducing or exposing a functional group on the resultant product.
- the prodrugs can be designed to react with an endogenous compound to form a water-soluble conjugate that further enhances the pharmacological properties of the compound, for example, increased circulatory half-life.
- prodrugs can be designed to undergo covalent modification on a functional group with, for example, glucuronic acid, sulfate, glutathione, amino acids, or acetate.
- the resulting conjugate can be inactivated and excreted in the urine, or rendered more potent than the parent compound.
- High molecular weight conjugates also can be excreted into the bile, subjected to enzymatic cleavage, and released back into circulation, thereby effectively increasing the biological half-life of the originally administered compound.
- the instant invention also includes the compounds which differ only in the presence of one or more isotopically enriched atoms for example replacement of hydrogen with deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon.
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium, iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
- Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn; salts of organic bases such as N,N′-diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine; chiral bases such as alkylphenylamine, glycinol, and phenyl glycinol; salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, and serine; quaternary ammonium salts of the compounds of invention with alkyl hal
- Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides (e.g., hydrochlorides), acetates, tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates. Salts can be formed by methods known in the art.
- cell proliferation refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.
- co-administration encompasses administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time.
- Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
- an effective amount refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below.
- the therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells, e.g. reduction of platelet adhesion and/or cell migration.
- the amount of compound administered ranges from about 0.1 mg to 5 g, from about 1 mg to 2.0 g, from about 100 mg to 1.5 g, from about 200 mg to 1.5 g, from about 400 mg to 1.5 g, and from about 400 mg to 1.0 g.
- the term “treating” refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
- a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
- the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- pharmaceutically acceptable excipient includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants/flavoring, carriers, buffers, stabilizers, solubilizers, and combinations thereof. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- a “subject” includes a mammal.
- the mammal can be e.g., any mammal, e.g., a human, primate, vertebrate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep or a pig.
- the mammal is a human.
- patient refers to a human subject.
- a “subject in need of” is a subject having a disease, disorder or condition, or a subject having an increased risk of developing a disease, disorder or condition relative to the population at large.
- the subject in need thereof can be one that is “non-responsive” or “refractory” to a currently available therapy for the disease or disorder, for example cancer.
- the terms “non-responsive” and “refractory” refer to the subject's response to therapy as not clinically adequate to relieve one or more symptoms associated with the disease or disorder.
- the subject in need thereof is a subject having cancer whose cancer is refractory to standard therapy or whose cancer has recurred following standard treatment.
- One embodiment is a pharmaceutical composition suitable for use in a subject, such as a human.
- the pharmaceutical composition may comprise at least one pharmaceutically acceptable excipient or carrier.
- the pharmaceutical composition may also include at least one additional active agent, such as an alkylating agent, an intercalating agent, a tubulin binding agent, a corticosteroid, or any combination of any of the foregoing.
- additional active agents include, but are not limited to, ibrutinib, rituximab, doxorubicin, prednisolone, vincristine, velcade, and everolimus,
- the at least one additional active agent is a therapeutic agent selected from cyclophosphamide, hydroxydaunorubicin (also referred to as doxorubicin) vincristine, prednisone, prednisolone, and any combination of any of the foregoing.
- the pharmaceutical composition may include one or more non-therapeutic agents, such as ondansetron, granisetron, dolasetron, palonosetron, pindolol, risperidone, or any combination of any of the foregoing.
- non-therapeutic agents such as ondansetron, granisetron, dolasetron, palonosetron, pindolol, risperidone, or any combination of any of the foregoing.
- a pharmaceutical composition can be provided as adosage unit form, such as an ampoule, a vial, a suppository, a dragee, a tablet, or a capsule.
- compositions can take any suitable form (e.g, liquids, aerosols, solutions, inhalants, mists, sprays; or solids, powders, ointments, pastes, creams, lotions, gels, patches and the like) for administration by any desired route (e.g, pulmonary, inhalatison, intranasal, oral, buccal, sublingual, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, intrapleural, intrathecal, transdermal, transmucosal, rectal, and the like).
- suitable route e.g, pulmonary, inhalatison, intranasal, oral, buccal, sublingual, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, intrapleural, intrathecal, transdermal, transmucosal, rectal, and the like.
- a pharmaceutical composition of the invention may be in the form of an aqueous solution or powder for aerosol administration by inhalation or insufflation (either through the mouth or the nose), in the form of a tablet or capsule for oral administration; in the form of a sterile aqueous solution or dispersion suitable for administration by either direct injection or by addition to sterile infusion fluids for intravenous infusion; or in the form of a lotion, cream, foam, patch, suspension, solution, or suppository for transdermal or transmucosal administration.
- a pharmaceutical composition can be in the form of an orally acceptable dosage form including, but not limited to, capsules, tablets, buccal forms, troches, lozenges, and oral liquids in the form of emulsions, aqueous suspensions, dispersions or solutions.
- Capsules may contain mixtures of a compound of the present invention with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
- starches e.g., corn, potato or tapioca starch
- sugars e.g., artificial sweetening agents
- powdered celluloses such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
- carriers which are commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, can also be added.
- useful diluents include lactose and dried corn starch.
- the compound of the present invention may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
- a pharmaceutical composition can be in the form of a tablet.
- the tablet can comprise a unit dosage of a compound of the present invention together with an inert diluent or carrier such as a sugar or sugar alcohol, for example lactose, sucrose, sorbitol or mannitol.
- the tablet can further comprise a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch.
- the tablet can further comprise binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g.
- swellable crosslinked polymers such as crosslinked carboxymethylcellulose
- lubricating agents e.g. stearates
- preservatives e.g. parabens
- antioxidants e.g. BHT
- buffering agents for example phosphate or citrate buffers
- effervescent agents such as citrate/bicarbonate mixtures.
- the compounds of the present invention may be prepared as follows.
- Starting intermediate A-1 is oxidized, for example by reaction with m-CPBA (meta-chloroperoxybenzoic acid) in a solvent, such as dichloromethane, to produce intermediate I.
- Intermediate I is then reacted with R 1 -L 2 H, for example, in the presence of a base (such as NaH) and in a solvent, such as THF, to form Intermediate A-3.
- Intermediate A-3 is first reacted with
- the compounds of the present invention are useful as PIKfyve kinase inhibitors.
- One embodiment a method of treating a subject having a neurological disease comprising administering to the subject an effective amount of a compound of the present invention (or a pharmaceutical composition of the present invention) to the subject.
- the subject is a human subject.
- the PIKfyve kinase inhibitors described herein may be used in the methods for treating a neurological disease described in U.S. Patent Publication No. 2018/0161335, which is hereby incorporated by reference in its entirety.
- the neurological disease may be one that has neuronal death generated by intracellular aggregates.
- the method includes treating amyotrophic lateral sclerosis (ALS). In certain embodiments, the method includes treating frontotemporal dementia (FTD). In certain embodiments, the method includes treating a neurological disease that is associated with aberrant endosomal trafficking. In certain embodiments, the method includes treating a neurological disease that is associated with aberrant lysosomal trafficking. In further embodiments, the method includes treating a subject who has a (GGGGCC)n repeat expansion in the C9ORF72 gene. In further embodiments, the subject is haploinsufficient for C9ORF72. In further embodiments the method includes treating patients who have a 50% or greater reduction in C9ORF72 protein activity.
- the method includes a C9ORF72 gene product that comprises a dipeptide repeat resulting from the (GGGGCC)n expansion. In further embodiments, the method includes a gain-of-function or loss of function mutation resulting from the (GGGGCC)n expansion. In further embodiments, the neurological disease is associated with neuronal hyperexcitability.
- One embodiment is a method of treating a subject having amyotrophic lateral sclerosis (ALS) comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- Another embodiment is a method of treating a subject having frontotemporal dementia (FTD) comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- Yet another embodiment is a method of treating a subject having Alzheimer's disease comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- Yet another embodiment is a method of treating a subject having Parkinson's disease comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- Yet another embodiment is a method of treating a subject having Huntington's disease comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- Yet another embodiment is a method of treating a subject having Charcot-Marie-Tooth disease (CMT) comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- CMT Charcot-Marie-Tooth disease
- the method may further comprise also administering an effective amount of a potassium channel activator, an inhibitor of a glutamate receptor (such as the receptor NMDA, AMPA, or kainite) (e.g., AP5, CNQX, and NBQX), or any combination of any of the foregoing.
- a potassium channel activator such as the receptor NMDA, AMPA, or kainite
- an inhibitor of a glutamate receptor such as the receptor NMDA, AMPA, or kainite
- AP5 e.g., AP5, CNQX, and NBQX
- PIKfyve is a phosphoinositide kinase (PIK) that contains a FYVE-type zinc finger domain, which binds phosphatidylinositol 3-phosphate (PI3P).
- PIKfyve phosphorylates PUP to produce PI(3,5)P 2 , which is involved in cellular processes including membrane trafficking and cytoskeletal reorganization.
- the inhibition of PIKfyve by a compound described herein is useful in treating not only cancer, but also Charcot-Marie-Tooth disease and certain viral infections, such as those caused by a virus selected from measles, Ebola virus (EboV), Marburg virus (MarV), borna disease, and human immunodeficiency virus (HIV), severe acute respiratory system virus (SARS), middle east respiratory syndrome virus (MERS), JC polyomavirus (JC), BK polyomavirus (BK), Herpes Simplex Virus (HSV), Venezuelan equine encephalitis virus (VEEV) and Lymphocytic choriomeningitis virus (LCMV).
- the viral infection can be caused by any type of virus such as RNA and DNA viruses.
- the virus is Ebola virus.
- the virus is middle east respiratory syndrome virus (MERS).
- the virus is JC polyomavirus (JC).
- the virus is BK polyomavirus (BK).
- the virus is Herpes Simplex Virus (HSV).
- HSV Herpes Simplex Virus
- the virus is Marburg virus (MarV).
- the virus is Venezuelan equine encephalitis virus (VEEV).
- the virus is Lymphocytic choriomeningitis virus (LCMV).
- One embodiment is a method for treating a cell proliferative disease, a cancer, or a viral infection in a subject, preferably a human subject, in need of such treatment, by administering an effective amount of a compound of the present invention or a pharmaceutical composition comprising same, to the subject.
- the cancer is brain cancer, glioma, sarcoma, breast cancer, lung cancer, non-small-cell lung cancer, mesothelioma, appendiceal cancer, genitourinary cancers, renal cell carcinoma, prostate cancer, bladder cancer, testicular cancer, penile cancer, cervical cancer, ovarian cancer, von Hippel Lindau disease, head and neck cancer, gastrointestinal cancer, hepatocellular carcinoma, gallbladder cancer, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, neuroendocrine tumors, thyroid tumor, pituitary tumor, adrenal tumor, hematological malignancy, or leukemia.
- the cancer is B cell lymphoma.
- the cancer is a melanoma.
- the cancer is a lymphoma.
- the lymphoma is a B cell lymphoma.
- the B cell lymphoma is selected from the group consisting of a Hodgkin's B cell lymphoma and a non-Hodgkin's B cell lymphoma.
- the B cell lymphoma is a non-Hodgkin's B cell lymphoma selected from the group consisting of DLBCL, follicular lymphoma, marginal zone lymphoma (MZL) or mucosa associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma (overlaps with chronic lymphocytic leukemia) and mantle cell lymphoma.
- DLBCL DLBCL
- follicular lymphoma follicular lymphoma
- MZL marginal zone lymphoma
- MALT mucosa associated lymphatic tissue lymphoma
- small cell lymphocytic lymphoma overlaps with chronic lymphocytic leukemia
- mantle cell lymphoma mantle cell lymphoma
- the B cell lymphoma is a non-Hodgkin's B cell lymphoma selected from the group consisting of Burkitt's lymphoma, Primary mediastinal (thymic) large B-cell lymphoma, Lymphoplasmacytic lymphoma, which may manifest as Waldenstrom macroglobulinemia, Nodal marginal zone B cell lymphoma (NMZL), Splenic marginal zone lymphoma (SMZL), Intravascular large B-cell lymphoma, Primary effusion lymphoma, Lymphomatoid granulomatosis, T cell/histiocyte-rich large B-cell lymphoma, Primary central nervous system lymphoma, Primary cutaneous diffuse large B-cell lymphoma, leg type (Primary cutaneous DLBCL, leg type), EBV positive diffuse large B-cell lymphoma of the elderly, Diffuse large B-cell lymphoma associated with inflammation, Intravascular large B-cell lymphoma, ALK-positive large B-
- the method is a method of treating a lymphoma using a combination therapy comprising a compound of the present invention and a chemotherapy regimen for the treatment of the lymphoma.
- the chemotherapy regimen is the CHOP regimen.
- the chemotherapy regimen is selected from COOP, CVP, EPOCH, Hyper-CVAD, ICE, R-CHOP, and R-CVP.
- the compounds can be administered by any suitable route, such as an oral, intravenous, or subcutaneous route.
- Intermediate VI was prepared by a method analogous to Intermediate V, except morpholine was added instead of Intermediate III.
- Intermediate VII was prepared by a method analogous to Intermediate IV, except tetrahydrofuran-2-yl)methanol was added in place of 2-(pyridin-2-yl)ethan-1-ol to generate the equivalent of Intermediate II and 5-(m-tolyl)-1H-pyrazole was added in place of 3-(3-methoxyphenyl)-1H-pyrazole to generate Intermediate VII.
- Tetrahydrofuran-2-yl)methanol (51 mg, 0.48 mmol) was added dropwise as a solution in THF (1 ml), and the solution stirred for 1 h at ⁇ 78° C., then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by silica gel chromatography (hexane/EtOAc) to give 16 mg of 4,6-dichloro-2-((tetrahydrofuran-2-yl)methoxy)pyrimidine.
- Tetrahydrofuran-2-yl)methanol (51 mg, 0.48 mmol) was added dropwise as a solution in THF (1 ml), and the solution stirred for 1 h at ⁇ 78° C., then quenched with water, extracted with EtOAc, dried (MgSO 4 ), filtered, evaporated and purified by silica gel chromatography (hexane/EtOAc) to give 23 mg of 4,6-dichloro-2-((tetrahydrofuran-2-yl)methoxy)pyrimidine.
- Compound 4 was prepared by a method analogous to that for Compound 1, except Intermediate III was used in place of morpholine and 5-phenyl-1H-pyrazole was used in place of 5-(3-methoxyphenyl)-1H-pyrazole.
- Compound 5 was prepared by a method analogous to that for Compound 1, except 2-(tert-butoxy)ethan-1-ol was added instead of tetrahydrofuran-2-yl)methanol, and the end product was treated with trifluoroacetic acid (TFA)/DCM 1:2 for 1 h at RT and evaporated prior to purification by LC/MS.
- TFA trifluoroacetic acid
- Compound 6 was prepared by a method analogous to that for Compound 1, except 2-(4-methylthiazol-5-yl)ethan-1-ol was added instead of tetrahydrofuran-2-yl)methanol.
- Compound 7 was prepared by a method analogous to that for Compound 6, except morpholine was used in place of Intermediate III.
- Compound 9 was prepared by a method analogous to that for Compound 8, except morpholine was used in place of Intermediate III.
- Compound 12 was prepared by a method analogous to that for Compound 11, except Intermediate VI was added instead of Intermediate V.
- Compound 15 was prepared by a method analogous to that for Compound 14.
- Compound 16 was prepared by a method analogous to that for Compound 4, except 5-(3-methoxyphenyl)-1H-pyrazole was added instead of 5-phenyl-1H-pyrazole.
- the activity of Compounds 1-20 was measured using a PIKFYVE assay (luciferase ADP-Glo kinase assay available from Promega Corp. of Madison, Wis.).
- the activity for each compound is provided in Table 1 below (“A” refers to an IC 50 of less than 5 nM, “B” refers to an IC 50 of 5-100 nM, “C” refers to an IC 50 of 101-1,000 nM, and “D” refers to an IC 50 of 1,001-10,000 nM).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 62/551,047, filed Aug. 28, 2017, which is hereby incorporated by reference.
- The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve).
- Apilimod is recognized as a potent transcriptional inhibitor of IL-12 and IL-23. See Wada et al., Blood 109 (2007):1156-1164. IL-12 and IL-23 are inflammatory cytokines normally produced by immune cells, such as B-cells and macrophages, in response to antigenic stimulation. Autoimmune disorders and other disorders characterized by chronic inflammation are characterized in part by inappropriate production of these cytokines. In immune cells, the selective inhibition of IL-12/IL-23 transcription by apilimod was recently shown to be mediated by apilimod's direct binding to phosphatidylinositol-3-phosphate 5-kinase (PIKfyve). See Cai et al., Chemistry and Biol. 20 (2013):912-921. PIKfyve plays a role in Toll-like receptor signaling, which is important in innate immunity.
- Based upon its activity as an immunomodulatory agent and a specific inhibitor of IL-12/IL-23, apilimod has been proposed as useful in treating autoimmune and inflammatory diseases and disorders. See U.S. Pat. Nos. 6,858,606 and 6,660,733 (describing a family of pyrimidine compounds, including apilimod, purportedly useful for treating diseases and disorders characterized by IL-12 or IL-23 overproduction, such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin dependent diabetes mellitus). Similarly, apilimod was suggested to be useful for treating certain cancers based upon its activity to inhibit c-Rel or IL-12/23, particularly in cancers where these cytokines were believed to play a role in promoting aberrant cell proliferation. See WO 2006/128129 and Baird et al., Frontiers in Oncology 3:1 (2013, respectively). International Publication No. WO 2016/210372 and U.S. Patent Publication No. 2018/0161335, which are hereby incorporated by reference, disclose methods of treating a neurological disease such as amyotrophic lateral sclerosis with a PIKFYVE kinase inhibitor.
- The present invention is directed to a compound of the formula (I)
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- each occurrence of R2 is independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- R3 is a nitrogen- or oxygen-containing moiety;
- Ring A is (i) a 5 or 6-membered heteroaryl or 5-6 or 6-5 membered bicyclic heteroaryl, each having at least one nitrogen or oxygen ring atom, or (ii) phenyl;
- L1 is absent, C1-C2 alkylene, —NRc—, —O—, —S—, —C(O)—, —NHC(O)—, or —C(O)NH—;
- L2 is —O—(CRaRb)m—, —(CRaRb)m—, —NRc—(CRaRb)m—, or —S—(CRaRb)m—;
- X1 is CH, N, or CRc;
- each occurrence of Ra and Rb are independently hydrogen, hydroxy, hydroxy(C1-4)alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl, halogen, nitro, —ORd, —SRd, —NRdRe, —C(O)Rd, —C(S)Rd, —OC(O)Rd, —SC(O)Rd, OC(S)Rd, SC(S)Rd, —NRcC(O)Rd, —NRcC(S)Rd, —SO2Rc, —S(O)Rc, —NRcSO2Rd, —(O)2Rd, —OP(O)RdRe, or —P(O)RdRe;
- Rc is a hydrogen or C1-6 alkyl (e.g., C1-C4 alkyl);
- each occurrence of Rd and Re are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- m is 1-4; and
- p is 1 or 2.
- These compounds are useful as PIKfyve kinase inhibitors.
- In one embodiment, R1 is heterocyclyl or heteroaryl. For example, R1 may be selected from (the squiggly lines indicate the point of attached to the rest of the molecule)
- In another embodiment, R1 is hydroxy.
- In one embodiment, each occurrence of R2 is independently substituted or unsubstituted aryl, such as a substituted or unsubstituted phenyl. For instance, R2 may be phenyl, a halogen-substituted phenyl, an alkyl-substituted phenyl (e.g., a C1-4 alkyl-substituted phenyl), a halogenated alkyl-substituted phenyl, or an alkoxy-substituted phenyl. In one embodiment, R2 is selected from phenyl, 3-methoxyphenyl, 3-methylphenyl, 3-trifluoromethylphenyl, and 3-chlorophenyl. In a preferred embodiment, R2 is selected from phenyl, 3-methoxyphenyl, and 3-methylphenyl.
- In another embodiment, each occurrence of R2 is independently substituted or unsubstituted alkyl (such as a C1-4 alkyl). For instance, R2 can be unsubstituted isopropyl.
- In one embodiment, R3 is a substituted or unsubstituted, saturated or unsaturated nitrogen- or oxygen-containing heterocyclyl. For instance, R3 can be a substituted or unsubstituted, saturated or unsaturated 5-10 membered (such as a 5-8 membered) mono- or bi-cyclic heterocyclyl having at least one nitrogen or oxygen ring atom. In one embodiment, R3 is a substituted or unsubstituted 5-10 membered (such as a 5-8 membered) mono- or bi-cyclic heterocyclyl having at least one nitrogen atom and optionally an oxygen ring atom, where the nitrogen ring atom is directly attached to the rest of the molecule. In one preferred embodiment, R3 is a substituted or unsubstituted (unsaturated) 5-membered monocyclic heterocyclyl having an oxygen ring atom or a nitrogen ring atom.
- In another embodiment, R3 is a substituted or unsubstituted, saturated or unsaturated 6-membered monocyclic heterocyclyl having an oxygen ring atom and optionally a nitrogen ring atom. In yet another embodiment, R3 is a saturated 8-membered bicyclic heterocyclyl having a nitrogen ring atom and an oxygen ring atom. In one embodiment, R3 is selected from
- In one preferred embodiment, R3 is selected from
- In another preferred embodiment, R3 is
- In yet another embodiment, R3 is a sulfonyl group of the formula —S(O)(CH2)qOR4, where R4 is hydrogen or C1-C4 alkyl and q is 1-4.
- In one embodiment, ring A is a 5-membered heteroaryl having at least one nitrogen ring atom. In one preferred embodiment, ring A includes two heteroatoms as ring atoms (such as two nitrogen ring atoms, or one nitrogen ring atom with one sulfur ring atom). In another preferred embodiment, ring A is selected from
- For instance, ring A can be selected from
- In one preferred embodiment, the R2 group in ring A above is selected from substituted or unsubstituted aryl, such as a substituted or unsubstituted phenyl. For instance, R2 may be phenyl, an alkyl-substituted, or an alkoxy-substituted phenyl. In a preferred embodiment, R2 is selected from phenyl, 3-methoxyphenyl, and 3-methylphenyl.
- In one embodiment, L1 is absent.
- In another embodiment, L1 is —NH—, —N(CH3)—, —O—, or —CH2—. In one embodiment, L1 is —NH—. In another embodiment, L1 is —C(O)NH— (where the carbonyl is attached to the rest of the molecule and the nitrogen is attached to ring A). In yet another embodiment, L1 is —NHC(O)— (where the nitrogen atom is attached to the rest of the molecule and the carbonyl is attached to ring A).
- In one embodiment, L2 is —O—(CRaRb)m—. In one preferred embodiment, L2 is —OCH2CH2— or —OCH2—. In another embodiment, L2 is —OCH2CH2CH(OH)CH2—.
- In another embodiment, L2 is —(CRaRb)m—. In one preferred embodiment, L2 is —CH2CH2—.
- In yet another embodiment, L2 is —NRc—(CRaRb)m—, such as —NH—(CRaRb)m— (e.g., —NH—, —NHCH2—, and —NHCH2CH2—).
- In one embodiment, -L2-R1 is —OCH2CH2CH(OH)CH2OH.
- In one preferred embodiment, X1 is CH. In another embodiment, X1 is N.
- In one embodiment, each occurrence of Ra and Rb are independently hydrogen, hydroxy, or hydroxy(C1-4)alkyl. In another embodiment, each occurrence of Ra and Rb are independently hydrogen or hydroxy.
- In one embodiment, m is 1. In another embodiment, m is 2. In a preferred embodiment, m is 1 or 2 when R1 is cyclic. In another preferred embodiment, m is 3 or 4 when R1 is acyclic.
- In a preferred embodiment, p is 1.
- In another embodiment, p is 2.
- In one preferred embodiment, the moiety
- is selected from
- Another embodiment is a compound of the formula (II)
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is hydroxy, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;
- R2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl;
- R3 is a substituted or unsubstituted oxygen-containing heterocyclyl;
- Ring A is a 5-membered heteroaryl having at least one nitrogen ring atom;
- L2 is —O—(CRaRb)m—;
- each occurrence of Ra and Rb are independently hydrogen, hydroxy, or hydroxy(C1-4)alkyl; and
- m is 1-4.
- In one embodiment of the compound of formula (II), R1 is heterocyclyl or heteroaryl. For example, R1 may be selected from
- In one embodiment of the compound of formula (II), R2 is substituted phenyl, such as an alkoxy-substituted phenyl, halogen-substituted phenyl, or alkyl-substituted phenyl. For example, R2 can be methoxyphenyl (e.g., 3-methoxyphenyl) or methylphenyl (e.g., 3-methylphenyl).
- In another embodiment of the compound of formula (II), R2 is hydroxy.
- In one preferred embodiment of the compound of formula (II), R3 is selected from
- In another preferred embodiment, R3 is
- In another preferred embodiment, R3 is
- In one embodiment of the compound of formula (II), ring A is a 5-membered heteroaryl having (i) two nitrogen ring atoms or (ii) one nitrogen ring atom and one sulfur ring atom. In another embodiment, ring A is selected from
- In one embodiment of the compound of formula (II), L2 is —OCH2—, —OCH2CH2—, —OCH2CH2CH(OH)CH2—, or —CH2CH2—. In one preferred embodiment, L2 is —OCH2—, —OCH2CH2—, or —OCH2CH2CH(OH)CH2—.
- Exemplary compounds of the present include those listed below and pharmaceutically salts thereof.
- Another embodiment is a method of inhibiting PIKfyve in a subject (such as a human subject) in need thereof comprising administering an effective amount of a compound of the present invention.
- Yet another embodiment is a method for treating a disease or disorder associated with PIKfyve in a human subject in need thereof comprising administering an effective amount of a compound of the present invention to the subject.
- Yet another embodiment is a method of treating a subject having a neurological disease comprising administering to the subject an effective amount of a compound of the present invention to the subject. In one embodiment, the neurological disease is amyotrophic lateral sclerosis (ALS). In another embodiment, the neurological disease is frontotemporal dementia (FTD). In yet another embodiment, the neurological disease is Alzheimer's disease. In yet another embodiment, the neurological disease is Parkinson's disease. In yet another embodiment, the neurological disease is Huntington's disease. In yet another embodiment, the neurological disease is Charcot-Marie-Tooth disease (CMT).
- In one embodiment, the effective amount of the compound is the amount effective to inhibit cellular PIKfyve activity in target cells in the subject. In another embodiment, the effective amount is the amount effective to induce vacuolization and disrupts intracellular trafficking in target cells.
- In one embodiment, the target cell is a cancer cell. In one embodiment, the cancer cell is a lymphoma cell. In one embodiment, the lymphoma cell is a non-Hodgkin's lymphoma cell.
- In one embodiment, the disease of disorder is selected from a cancer, a viral infection, or a cell proliferative disorder. For example, the cancer can be a lymphoma or melanoma. In one embodiment, the cancer is refractory or resistant to standard therapy. In one embodiment, the cancer is a non-Hodgkin's lymphoma.
- One embodiment is a method of treating a viral infection in a subject in need thereof comprising administering an effective amount of a compound of the present invention to the subject. The viral infection can be caused by any type of virus such as RNA and DNA viruses. In one embodiment, the virus is Ebola virus. In another embodiment, the virus is middle east respiratory syndrome virus (MERS). In yet another embodiment, the virus is JC polyomavirus (JC). In yet another embodiment, the virus is BK polyomavirus (BK). In yet another embodiment, the virus is Herpes Simplex Virus (HSV). In yet another embodiment, the virus is Marburg virus (MarV). In yet another embodiment, the virus is Venezuelan equine encephalitis virus (VEEV). In yet another embodiment, the virus is Lymphocytic choriomeningitis virus (LCMV).
- Another embodiment is method of treating Charcot-Marie-Tooth disease (CMT) in a subject, preferably a human subject, in need of such treatment, by administering an effective amount of a compound of the present invention to the subject.
- One embodiment is a method for treating a lymphoma comprising administering (e.g., an effective amount of) a compound of the present invention and at least one additional active agent. In one embodiment, the at least one additional active agent is selected from ibrutinib, rituximab, doxorubicin, prednisolone, vincristine, velcade, and everolimus, and combinations thereof. In one embodiment, the method includes a therapeutic regimen comprising administering a compound of the present invention and a CHOP regimen.
- In one embodiment, the method is a method for treating melanoma and the method further comprises administering at least one additional active agent to the subject in a therapeutic regimen comprising a compound of the present invention and the at least one additional active agent. In one embodiment, the at least one additional active agent is selected from dacarbazine, temozolomide, Nab-paclitaxel, carmustine, cisplatin, carboplatin, or vinblastine.
- In one embodiment, the method is a method for treating a viral infection and the method further comprises administering at least one additional active agent to the subject in a therapeutic regimen comprising a compound of the present invention and the at least one additional active agent. In one embodiment, the at least one additional active agent is selected from selected from the group consisting of apilimod, APY0201, and YM-201636.
- In accordance with any of the methods described herein, a compound of the present invention may also be administered in combination with a non-therapeutic agent which mitigates one or more side effects associated with the compound or increases the bioavailability of the compound. In one embodiment, the non-therapeutic agent is selected from the group consisting of ondansetron, granisetron, dolasetron and palonosetron. In another aspect, the non-therapeutic agent is selected from the group consisting of pindolol and risperidone. In another aspect, the non-therapeutic agent is selected from a cytochrome P450 3A (CYP3A) inhibitor. In one embodiment, the CYP3A inhibitor is selected from ritonavir and cobicistat.
- In one embodiment, the viral infection is caused by a virus selected from the group consisting of measles, Ebola (EboV), Marburg (MarV), borna disease, and human immunodeficiency virus (HIV), severe acute respiratory system virus (SARS), and middle east respiratory syndrome virus (MERS). In one embodiment, the viral infection is caused by an EboV virus.
- In one embodiment, the compound is in the form a pharmaceutical composition comprising the compound and at least one pharmaceutically acceptable carrier.
- In one embodiment, the compound comprises at least 95% or at least 99% enantiomeric excess of the (R)-enantiomer. In one embodiment, the compound comprises at least 95% or at least 99% enantiomeric excess of the (S)-enantiomer.
- Another embodiment is pharmaceutical composition comprising a compound of the present invention wherein the compound comprises at least 95% or at least 99% enantiomeric excess of the (R)-enantiomer or the (S)-enantiomer.
- As used herein the following definitions shall apply unless otherwise indicated. Further, many of the groups defined herein can be optionally substituted. The listing of substituents in the definition is exemplary and is not to be construed to limit the substituents defined elsewhere in the specification.
- The term “alkyl”, unless otherwise specified, refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (t-butyl). The term “C1-6 alkyl” refers to an alkyl group as defined above having up to 6 carbon atoms. The term “C1-3 alkyl” refers to an alkyl group as defined above having up to 3 carbon atoms. In appropriate circumstances, the term “alkyl” refers to a hydrocarbon chain radical as mentioned above which is bivalent.
- The term “alkenyl”, unless otherwise specified, refers to an aliphatic hydrocarbon group containing one or more carbon-carbon double bonds and which may be a straight or branched or branched chain having about 2 to about 10 carbon atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, and 2-butenyl. The term “C2-6 alkenyl” refers to an alkenyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term “alkenyl” refers to a hydrocarbon group as mentioned above which is bivalent.
- The term “alkynyl”, unless otherwise specified, refers to a straight or branched chain hydrocarbyl radical having at least one carbon-carbon triple bond, and having in the range of 2 to up to 12 carbon atoms (with radicals having in the range of 2 to up to 10 carbon atoms presently being preferred) e.g., ethynyl, propynyl, and butnyl. The term “C2-6 alkynyl” refers to an alkynyl group as defined above having up to 6 carbon atoms. In appropriate circumstances, the term “alkynyl” refers to a hydrocarbyl radical as mentioned above which is bivalent.
- The term “alkoxy” unless otherwise specified, denotes an alkyl, cycloalkyl, or cycloalkylalkyl group as defined above attached via an oxygen linkage to the rest of the molecule. The term “substituted alkoxy” refers to an alkoxy group where the alkyl constituent is substituted (i.e., -0-(substituted alkyl). For example “alkoxy” refers to the group —O-alkyl, including from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, and cyclohexyloxy. In appropriate circumstances, the term “alkoxy” refers to a group as mentioned above which is bivalent.
- The term “cycloalkyl”, unless otherwise specified, denotes a non-aromatic mono or multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include perhydronaphthyl, adamantyl and norbornyl groups, bridged cyclic groups, and sprirobicyclic groups, e.g., sprio (4,4) non-2-yl. The term “C3-6 cycloalkyl” refers to a cycloalkyl group as defined above having up to 6 carbon atoms.
- The term “cycloalkylalkyl”, unless otherwise specified, refers to a cyclic ring-containing radical containing in the range of about 3 up to 8 carbon atoms directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group, such as cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl.
- The term “cycloalkenyl”, unless otherwise specified, refers to cyclic ring-containing radicals containing in the range of about 3 up to 8 carbon atoms with at least one carbon-carbon double bond such as cyclopropenyl, cyclobutenyl, and cyclopentenyl. The term “cycloalkenylalkyl” refers to a cycloalkenyl group directly attached to an alkyl group which is then attached to the main structure at any carbon from the alkyl group.
- The term “aryl”, unless otherwise specified, refers to aromatic radicals having in the range of 6 up to 20 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl.
- The term “arylalkyl”, unless otherwise specified, refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., —CH2C6H5 and —C2H5C6H5.
- The term “heterocyclic ring”, unless otherwise specified, refers to a non-aromatic 3 to 15 member ring radical which consists of carbon atoms and at least one heteroatom selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a mono-, bi-, tri- or tetracyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom.
- The term “heterocyclyl”, unless otherwise specified, refers to a heterocylic ring radical as defined above. The heterocylcyl ring radical may be attached to the main structure at any heteroatom or carbon ring atom. In appropriate circumstances, the term “heterocyclyl” refers to a hydrocarbon chain radical as mentioned above which is bivalent.
- The term “heterocyclylalkyl”, unless otherwise specified, refers to a heterocylic ring radical as defined above directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group. Examples of such heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.
- The term “heteroaryl”, unless otherwise specified, refers to an optionally substituted 5 to 14 member aromatic ring having one or more heteroatoms selected from N, O, and S as ring atoms. The heteroaryl may be a mono-, bi- or tricyclic ring system. Examples of such “heteroaryl” radicals include, but are not limited to, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, carbazolyl, quinolyl, isoquinolyl, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyrrolidinyl, pyridazinyl, oxazolinyl, oxazolidinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothienyl, thiamo holinyl, thiamorpholinyl sulfoxide, thiamo holinyl sulfone, dioxaphospholanyl, oxadiazolyl, chromanyl, and isochromanyl.
- The term “5 or 6-membered heteroaryl” refers to a heteroaryl having 5- or 6-ring atoms. The term “5-6 or 6-5 membered bicyclic heteroaryl” refers to a bicyclic heteroaryl with a five-membered ring fused to a six-membered ring, where the 5-membered ring is bound to the rest of the molecule (referred as a “5-6 membered bicyclic heteroaryl”) or the 6-membered ring is bound to the rest of the molecule (referred as a “6-5 membered bicyclic heteroaryl”).
- The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom. The term “substituted heteroaryl” also includes ring systems substituted with one or more oxide (—O—) substituents, such as pyridinyl N-oxides.
- The term “heteroarylalkyl”, unless otherwise specified, refers to a heteroaryl ring radical as defined above directly bonded to an alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom from alkyl group.
- The term “cyclic ring” refers to a cyclic ring containing 3 to 10 carbon atoms.
- The term “substituted” unless otherwise specified, refers to substitution with any one or any combination of the following substituents which may be the same or different and are independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, substituted or unsubstituted guanidine, —COORx, —C(O)Rx, —C(S)RX, —C(O)NRxRy, —C(O)ONRxRy, —NRyRz, —NRxCONRyRz, —N(Rx)SORy, —N(Rx)SO2Ry, ═N—NRxRy, —NRxC(O)ORy, —NRxRy, —NRxC(O)Ry, —NRxC(S)Ry—NRxC(S)NRyRz, —SONRxRy, —SO2NRxRy, —ORx, —ORxC(O)NRyRz, —ORxC(O)ORy, —OC(O)Rx, —OC(O)NRxRy, —RxNRyC(O)Rz, —RxORy, —RxC(O)ORy, —RxC(O)NRyRz, —RxC(O)Rx, —RxOC(O)Ry, —SRx, —SORx, —SO2Rx, and —ONO2, wherein Rx, Ry and Rz in each of the above groups can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, or substituted heterocyclylalkyl ring, or any two of Rx, Ry and Rz may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10 membered ring, which may optionally include heteroatoms which may be the same or different and are selected from O, NRx (e.g., Rx can be hydrogen or C1-6 alkyl) or S. Substitution or the combinations of substituents envisioned by this invention are preferably those that result in the formation of a stable or chemically feasible compound. The term stable as used herein refers to the compounds or the structure that are not substantially altered when subjected to conditions to allow for their production, detection and preferably their recovery, purification and incorporation into a pharmaceutical composition. The substituents in the aforementioned “substituted” groups cannot be further substituted. For example, when the substituent on “substituted alkyl” is “substituted aryl”, the substituent on “substituted aryl” cannot be “substituted alkenyl”.
- The term “halo”, “halide”, or, alternatively, “halogen” means fluoro, chloro, bromo or iodo. The terms “haloalkyl,” “haloalkenyl,” “haloalkynyl” and “haloalkoxy” include alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof. For example, the terms “fluoroalkyl” and “fluoroalkoxy” include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
- The term “protecting group” or “PG” refers to a substituent that is employed to block or protect a particular functionality. Other functional groups on the compound may remain reactive. For example, an “amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include, but are not limited to, acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a “hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxy-protecting groups include, but are not limited to, acetyl and silyl. A “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Suitable carboxy-protecting groups include, but are not limited to, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, and nitroethyl. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
- Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Non-limiting examples of intermediate mixtures include a mixture of isomers in a ratio of 10:90, 13:87, 17:83, 20:80, or 22:78. Optically active (R)- and (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
- A “leaving group or atom” is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms and mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.
- The term “prodrug” refers to a compound, which is an inactive precursor of a compound, converted into its active form in the body by normal metabolic processes. Prodrug design is discussed generally in Hardma, et al. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A thorough discussion is provided in Higuchi, et al., Prodrugs as Novel Delivery Systems, Vol. 14, ASCD Symposium Series, and in Roche (ed.), Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987). To illustrate, prodrugs can be converted into a pharmacologically active form through hydrolysis of, for example, an ester or amide linkage, thereby introducing or exposing a functional group on the resultant product. The prodrugs can be designed to react with an endogenous compound to form a water-soluble conjugate that further enhances the pharmacological properties of the compound, for example, increased circulatory half-life. Alternatively, prodrugs can be designed to undergo covalent modification on a functional group with, for example, glucuronic acid, sulfate, glutathione, amino acids, or acetate. The resulting conjugate can be inactivated and excreted in the urine, or rendered more potent than the parent compound. High molecular weight conjugates also can be excreted into the bile, subjected to enzymatic cleavage, and released back into circulation, thereby effectively increasing the biological half-life of the originally administered compound.
- Additionally, the instant invention also includes the compounds which differ only in the presence of one or more isotopically enriched atoms for example replacement of hydrogen with deuterium or tritium, or the replacement of a carbon by 13C- or 14C-enriched carbon.
- The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium, iodine-125 (125I) or carbon-14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
- Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn; salts of organic bases such as N,N′-diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine; chiral bases such as alkylphenylamine, glycinol, and phenyl glycinol; salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, and serine; quaternary ammonium salts of the compounds of invention with alkyl halides, and alkyl sulphates. Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides (e.g., hydrochlorides), acetates, tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates. Salts can be formed by methods known in the art.
- When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term “about” when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary from, for example, between 1% and 15% of the stated number or numerical range.
- The term “cell proliferation” refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.
- The term “co-administration,” “administered in combination with,” and their grammatical equivalents, as used herein, encompasses administration of two or more agents to an animal so that both agents and/or their metabolites are present in the animal at the same time. Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
- The term “effective amount” or “therapeutically effective amount” refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g. reduction of platelet adhesion and/or cell migration. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried. In one embodiment, the amount of compound administered ranges from about 0.1 mg to 5 g, from about 1 mg to 2.0 g, from about 100 mg to 1.5 g, from about 200 mg to 1.5 g, from about 400 mg to 1.5 g, and from about 400 mg to 1.0 g.
- As used herein, the term “treating” refers to an approach for obtaining beneficial or desired results including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. For prophylactic benefit, the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- A “therapeutic effect,” as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- The term “pharmaceutically acceptable excipient” includes, but is not limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorants/flavoring, carriers, buffers, stabilizers, solubilizers, and combinations thereof. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions of the invention is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- A “subject” includes a mammal. The mammal can be e.g., any mammal, e.g., a human, primate, vertebrate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep or a pig. Preferably, the mammal is a human. The term “patient” refers to a human subject.
- In accordance with the methods described herein, a “subject in need of” is a subject having a disease, disorder or condition, or a subject having an increased risk of developing a disease, disorder or condition relative to the population at large. The subject in need thereof can be one that is “non-responsive” or “refractory” to a currently available therapy for the disease or disorder, for example cancer. In this context, the terms “non-responsive” and “refractory” refer to the subject's response to therapy as not clinically adequate to relieve one or more symptoms associated with the disease or disorder. In one aspect of the methods described here, the subject in need thereof is a subject having cancer whose cancer is refractory to standard therapy or whose cancer has recurred following standard treatment.
- One embodiment is a pharmaceutical composition suitable for use in a subject, such as a human. The pharmaceutical composition may comprise at least one pharmaceutically acceptable excipient or carrier.
- The pharmaceutical composition may also include at least one additional active agent, such as an alkylating agent, an intercalating agent, a tubulin binding agent, a corticosteroid, or any combination of any of the foregoing. Examples of additional active agents include, but are not limited to, ibrutinib, rituximab, doxorubicin, prednisolone, vincristine, velcade, and everolimus, In one embodiment, the at least one additional active agent is a therapeutic agent selected from cyclophosphamide, hydroxydaunorubicin (also referred to as doxorubicin) vincristine, prednisone, prednisolone, and any combination of any of the foregoing.
- The pharmaceutical composition may include one or more non-therapeutic agents, such as ondansetron, granisetron, dolasetron, palonosetron, pindolol, risperidone, or any combination of any of the foregoing.
- A pharmaceutical composition can be provided as adosage unit form, such as an ampoule, a vial, a suppository, a dragee, a tablet, or a capsule.
- The pharmaceutical compositions can take any suitable form (e.g, liquids, aerosols, solutions, inhalants, mists, sprays; or solids, powders, ointments, pastes, creams, lotions, gels, patches and the like) for administration by any desired route (e.g, pulmonary, inhalatison, intranasal, oral, buccal, sublingual, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, intrapleural, intrathecal, transdermal, transmucosal, rectal, and the like). For example, a pharmaceutical composition of the invention may be in the form of an aqueous solution or powder for aerosol administration by inhalation or insufflation (either through the mouth or the nose), in the form of a tablet or capsule for oral administration; in the form of a sterile aqueous solution or dispersion suitable for administration by either direct injection or by addition to sterile infusion fluids for intravenous infusion; or in the form of a lotion, cream, foam, patch, suspension, solution, or suppository for transdermal or transmucosal administration.
- A pharmaceutical composition can be in the form of an orally acceptable dosage form including, but not limited to, capsules, tablets, buccal forms, troches, lozenges, and oral liquids in the form of emulsions, aqueous suspensions, dispersions or solutions. Capsules may contain mixtures of a compound of the present invention with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, can also be added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the compound of the present invention may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
- A pharmaceutical composition can be in the form of a tablet. The tablet can comprise a unit dosage of a compound of the present invention together with an inert diluent or carrier such as a sugar or sugar alcohol, for example lactose, sucrose, sorbitol or mannitol. The tablet can further comprise a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch. The tablet can further comprise binding and granulating agents such as polyvinylpyrrolidone, disintegrants (e.g. swellable crosslinked polymers such as crosslinked carboxymethylcellulose), lubricating agents (e.g. stearates), preservatives (e.g. parabens), antioxidants (e.g. BHT), buffering agents (for example phosphate or citrate buffers), and effervescent agents such as citrate/bicarbonate mixtures.
- The compounds of the present invention may be prepared as follows.
- Starting intermediate A-1 is oxidized, for example by reaction with m-CPBA (meta-chloroperoxybenzoic acid) in a solvent, such as dichloromethane, to produce intermediate I. Intermediate I is then reacted with R1-L2H, for example, in the presence of a base (such as NaH) and in a solvent, such as THF, to form Intermediate A-3. Intermediate A-3 is first reacted with
- and then with R3—H to form the final compound.
- The compounds of the present invention are useful as PIKfyve kinase inhibitors.
- One embodiment a method of treating a subject having a neurological disease comprising administering to the subject an effective amount of a compound of the present invention (or a pharmaceutical composition of the present invention) to the subject. In a preferred embodiment, the subject is a human subject. The PIKfyve kinase inhibitors described herein may be used in the methods for treating a neurological disease described in U.S. Patent Publication No. 2018/0161335, which is hereby incorporated by reference in its entirety. For example, the neurological disease may be one that has neuronal death generated by intracellular aggregates.
- In certain embodiments, the method includes treating amyotrophic lateral sclerosis (ALS). In certain embodiments, the method includes treating frontotemporal dementia (FTD). In certain embodiments, the method includes treating a neurological disease that is associated with aberrant endosomal trafficking. In certain embodiments, the method includes treating a neurological disease that is associated with aberrant lysosomal trafficking. In further embodiments, the method includes treating a subject who has a (GGGGCC)n repeat expansion in the C9ORF72 gene. In further embodiments, the subject is haploinsufficient for C9ORF72. In further embodiments the method includes treating patients who have a 50% or greater reduction in C9ORF72 protein activity. In further embodiments, the method includes a C9ORF72 gene product that comprises a dipeptide repeat resulting from the (GGGGCC)n expansion. In further embodiments, the method includes a gain-of-function or loss of function mutation resulting from the (GGGGCC)n expansion. In further embodiments, the neurological disease is associated with neuronal hyperexcitability.
- One embodiment is a method of treating a subject having amyotrophic lateral sclerosis (ALS) comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject. Another embodiment is a method of treating a subject having frontotemporal dementia (FTD) comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject. Yet another embodiment is a method of treating a subject having Alzheimer's disease comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject. Yet another embodiment is a method of treating a subject having Parkinson's disease comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject. Yet another embodiment is a method of treating a subject having Huntington's disease comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject. Yet another embodiment is a method of treating a subject having Charcot-Marie-Tooth disease (CMT) comprising administering to the subject (preferably a human subject) an effective amount of a compound of the present invention to the subject.
- The method may further comprise also administering an effective amount of a potassium channel activator, an inhibitor of a glutamate receptor (such as the receptor NMDA, AMPA, or kainite) (e.g., AP5, CNQX, and NBQX), or any combination of any of the foregoing.
- PIKfyve is a phosphoinositide kinase (PIK) that contains a FYVE-type zinc finger domain, which binds phosphatidylinositol 3-phosphate (PI3P). PIKfyve phosphorylates PUP to produce PI(3,5)P2, which is involved in cellular processes including membrane trafficking and cytoskeletal reorganization. The inhibition of PIKfyve by a compound described herein is useful in treating not only cancer, but also Charcot-Marie-Tooth disease and certain viral infections, such as those caused by a virus selected from measles, Ebola virus (EboV), Marburg virus (MarV), borna disease, and human immunodeficiency virus (HIV), severe acute respiratory system virus (SARS), middle east respiratory syndrome virus (MERS), JC polyomavirus (JC), BK polyomavirus (BK), Herpes Simplex Virus (HSV), Venezuelan equine encephalitis virus (VEEV) and Lymphocytic choriomeningitis virus (LCMV). The viral infection can be caused by any type of virus such as RNA and DNA viruses.
- One embodiment is a method of treating a viral infection in a subject in need thereof comprising administering an effective amount of a compound of the present invention to the subject. In one embodiment, the virus is Ebola virus. In another embodiment, the virus is middle east respiratory syndrome virus (MERS). In yet another embodiment, the virus is JC polyomavirus (JC). In yet another embodiment, the virus is BK polyomavirus (BK). In yet another embodiment, the virus is Herpes Simplex Virus (HSV). In yet another embodiment, the virus is Marburg virus (MarV). In yet another embodiment, the virus is Venezuelan equine encephalitis virus (VEEV). In yet another embodiment, the virus is Lymphocytic choriomeningitis virus (LCMV).
- One embodiment is a method for treating a cell proliferative disease, a cancer, or a viral infection in a subject, preferably a human subject, in need of such treatment, by administering an effective amount of a compound of the present invention or a pharmaceutical composition comprising same, to the subject.
- The compounds described herein are useful for treating cancer. In one embodiment, the cancer is brain cancer, glioma, sarcoma, breast cancer, lung cancer, non-small-cell lung cancer, mesothelioma, appendiceal cancer, genitourinary cancers, renal cell carcinoma, prostate cancer, bladder cancer, testicular cancer, penile cancer, cervical cancer, ovarian cancer, von Hippel Lindau disease, head and neck cancer, gastrointestinal cancer, hepatocellular carcinoma, gallbladder cancer, esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, neuroendocrine tumors, thyroid tumor, pituitary tumor, adrenal tumor, hematological malignancy, or leukemia. In another embodiment, the cancer is B cell lymphoma. In another embodiment, the cancer is a melanoma.
- In one embodiment the cancer is a lymphoma. In one embodiment, the lymphoma is a B cell lymphoma. In one embodiment, the B cell lymphoma is selected from the group consisting of a Hodgkin's B cell lymphoma and a non-Hodgkin's B cell lymphoma. In one embodiment, the B cell lymphoma is a non-Hodgkin's B cell lymphoma selected from the group consisting of DLBCL, follicular lymphoma, marginal zone lymphoma (MZL) or mucosa associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma (overlaps with chronic lymphocytic leukemia) and mantle cell lymphoma. In one embodiment, the B cell lymphoma is a non-Hodgkin's B cell lymphoma selected from the group consisting of Burkitt's lymphoma, Primary mediastinal (thymic) large B-cell lymphoma, Lymphoplasmacytic lymphoma, which may manifest as Waldenstrom macroglobulinemia, Nodal marginal zone B cell lymphoma (NMZL), Splenic marginal zone lymphoma (SMZL), Intravascular large B-cell lymphoma, Primary effusion lymphoma, Lymphomatoid granulomatosis, T cell/histiocyte-rich large B-cell lymphoma, Primary central nervous system lymphoma, Primary cutaneous diffuse large B-cell lymphoma, leg type (Primary cutaneous DLBCL, leg type), EBV positive diffuse large B-cell lymphoma of the elderly, Diffuse large B-cell lymphoma associated with inflammation, Intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, and Plasmablastic lymphoma.
- In one embodiment, the method is a method of treating a lymphoma using a combination therapy comprising a compound of the present invention and a chemotherapy regimen for the treatment of the lymphoma. In one embodiment, the chemotherapy regimen is the CHOP regimen. In another embodiment, the chemotherapy regimen is selected from COOP, CVP, EPOCH, Hyper-CVAD, ICE, R-CHOP, and R-CVP.
- In the methods described here, the compounds can be administered by any suitable route, such as an oral, intravenous, or subcutaneous route.
- The examples are illustrative only and do not limit the claimed invention.
-
- To a solution of 4,6-dichloro-2-(methylthio)pyrimidine (9.75 g, 50 mmol) in dichloromethane (DCM) was slowly added meta-chloroperoxybenzoic acid (mCPBA) 22.4 g, 130 mmol) at 0° C. The reaction was allowed to warm to room temperature (RT) and stirred overnight. The mixture was quenched with an aqueous solution of IM NaOH, extracted with DCM, washed with sat. aq. NaHCO3 as well as brine, and the organic phase dried (MgSO4), filtered and evaporated to give Intermediate I, 4,6-dichloro-2-(methylsulfonyl)pyrimidine, as a white solid (11.39 g). The product was used crude.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=0.94 min, (M+H)+ 227
- 1H NMR (300 MHz DMSO-d6): δ 8.30 (1H, s), 3.32 (3H, s)
-
- To a solution of Intermediate I (11.3 g, 50 mmol) in tetrahydrofuran (THF) (60 ml) was added NaH (2.9 g, 72.5 mmol). The temperature was lowered to −78° C. and 2-(pyridin-2-yl)ethan-1-ol (6.5 g, 52.5 mmol) in THF (60 ml) was added dropwise. The reaction was stirred for 1 h at −78° C., and worked up by addition of water, followed by extraction with ethyl acetate (EtOAc), dried (MgSO4), filtered and evaporated. The crude product was purified by silica gel chromatography using a gradient of hexane:EtOAc 9:1 to hexane:EtOAc 7:3. After evaporation of the correct fractions, 6.7 g of Intermediate II, 4,6-dichloro-2-(2-pyridin-2-yl)ethoxy)pyrimidine was obtained as a white solid.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=1.68 min, (M+H)+ 270
- 1H NMR (300 MHz DMSO-d6): δ 8.43 (1H, d), 7.66 (2H, m), 7.22 (1H, d), 7.15 (1H, m), 4.21 (2H, m), 3.29 (2H, m)
-
- To a solution of furan-2-carbaldehyde and ethyl 2-azidopropanoate in ethanol (EtOH) was added sodium ethoxide (1.1 eq) and the reaction heated at reflux overnight. Evaporated, redissolved in ethyl acetate, and washed with sat. aq. sodium bicarbonate, the organic phase dried (MgSO4), filtered and evaporated. The crude product was redissolved in xylene and heated at 160° C. for 4 hours, then evaporated and purified by silica gel chromatography (EtOAc/hexane). Re-dissolved in ACN, 4-Dimethylaminopyridine (DMAP) added (0.1 eq) and Boc2O and stirred at rt for 5 h, worked up (as before), redissolved in EtOH and hydrogenated at 40 psi with Pd/C 105 for 2 h. Evaporated and treated with sat. aq. LiOH in THF at RT for 2 h. Evaporated and purified by LC/MS. The solid was redissolved in TFA/DCM 1:2 and stirred and rt for 2 h, evaporated, decarboxylated by heating, purified by LC/MS and covered to the HCl salt.
- 1H NMR (300 MHz DMSO-d6): δ 83.68 (3H, m), 2.79 (3H, m), 2.01 (3H, m), 1.76 (2H, m)
-
- To a solution of Intermediate II, 4,6-dichloro-2-(2-(pyridin-2-yl)ethoxy)pyrimidine (269 mg, 1 mmol) in DMF (10 ml) was added 3-(3-methoxyphenyl)-1H-pyrazole (191 mg, 1.1 mmol) and NaH (19 mg, 1.2 mmol). The reaction was stirred at RT overnight, quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by LCMS to give 4-chloro-6-(3-phenyl-1H-pyrazol-1-yl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidine (Intermediate IV) (188 mg).
- LC/MS (M+H)+ 408
- 1H NMR (300 MHz DMSO-d6): δ 8.43 (1H, m), 8.09 (1H, m), 7.76 (1H, s), 7.72 (2H, m), 7.47 (1H, m), 7.39 (1H, s), 7.18 (3H, m), 6.95 (1H, m), 4.25 (2H, m), 3.81 (3H, S), 3.30 (2H, m),
-
- To 2.8 g of Intermediate I (12.3 mml) was added NaH (770 mg, 32 mmol) and tetrahydrofuran-2-yl)methanol (1.81 g, 16 mmol) at 0° C. in THF (200 ml). The reaction was stirred at 2 h at RT, and Intermediate III (1.81 g, 16 mmol) added, and the reaction stirred overnight at RT. The reaction was worked up by quenching with water, evaporation, re-dissolved in ethyl acetate, washed (saturated aq. sodium bicarbonate), dried (MgSO4), filtered and evaporated. The crude mixture was purified by silica gel chromatography (hexane/ethyl acetate) to give 2.2 g of Intermediate V.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.36 min, (M+H)+ 326
- 1H NMR (300 MHz CDCl3): δ 7.29 (s, 1H), 4.49 (m, 5H), 3.37 (m, 6H), 2.24 (m, 2H), 2.13 (m, 1H), 1.90 (m, 5H)
-
- Intermediate VI was prepared by a method analogous to Intermediate V, except morpholine was added instead of Intermediate III.
- LC/MS (mobile phase 5-100% ACN in 4 min), Rt=2.22 min, (M+H)+ 300
- 1H NMR (300 MHz DMSO-d6): δ 6.62 (s, 1H), 4.19 (m, 1H), 4.14 (m, 1H), 3.77 (m, 1H), 3.62 (m, 9H), 1.97 (m, 1H), 1.85 (m, 2H), 1.62 (m, 1H)
-
- Intermediate VII was prepared by a method analogous to Intermediate IV, except tetrahydrofuran-2-yl)methanol was added in place of 2-(pyridin-2-yl)ethan-1-ol to generate the equivalent of Intermediate II and 5-(m-tolyl)-1H-pyrazole was added in place of 3-(3-methoxyphenyl)-1H-pyrazole to generate Intermediate VII.
- LC/MS (mobile phase 5-100% ACN in 4 min), Rt=3.52 min, (M+H)+ 371
- 1H NMR (300 MHz DMSO-d6): δ 8.75 (s, 1H), 7.77 (s, 1H), 7.81 (d, 1H), 7.68 (s, 1H), 7.39 (m, 1H), 7.27 (m, 1H), 7.21 (s, 1H), 4.40 (m, 2H), 2.16 (m, 1H), 3.83 (m, 1H0, 3.72 (m, 1H), 2.40 (s, 3H), 2.06 (m, 1H), 1.88 (m, 2H), 1.72 (m, 1H)
-
- Intermediate VIII was prepared by the scheme shown above.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=4.32 min, (M+H)+ 369
- 1H NMR (300 MHz DMSO-d6): δ 8.72 (s, 1H), 7.89 (m, 2H), 7.81 (m, 1H), 7.39 (m, 1H), 7.26 (m, 1H), 7.20 (s, 1H), 3.82 (m, 1H), 3.75 (m, 1H), 3.60 (m, 1H), 2.90 (m, 2H), 2.40 (s, 3H), 2.00 (m, 3H), 1.82 (m, 2H), 1.49 (m, 1H)
-
- To a solution of Intermediate I, 4,6-dichloro-2-(methylsulfonyl)pyrimidine (113 mg, 0.5 mmol) in THF (5 ml), was added NaH (14 mg, 0.64 mmol) and the solution cooled to −78° C. Tetrahydrofuran-2-yl)methanol (51 mg, 0.48 mmol) was added dropwise as a solution in THF (1 ml), and the solution stirred for 1 h at −78° C., then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by silica gel chromatography (hexane/EtOAc) to give 16 mg of 4,6-dichloro-2-((tetrahydrofuran-2-yl)methoxy)pyrimidine. This was dissolved in dimethylformamide (DMF) (1 ml), NaH (4 mg, 0.18 mmol) was added, followed by 5-(3-methoxyphenyl)-1H-pyrazole (16 mg, 0.09 mmol), and the reaction mixture stirred for 1 h at RT. Intermediate III (44 mg) was added, and the reaction stirred overnight at RT, then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by LC/MS to give 8 mg of (3aR,6aR)-4-(6-(3-(3-methoxyphenyl)-1H-pyrazol-1-yl)-2-((tetrahydrofuran-2-yl)methoxy)pyrimidin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole Compound 1.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.91 min, (M+H)+ 464
-
- To a solution of Intermediate I, 4,6-dichloro-2-(methylsulfonyl)pyrimidine (113 mg, 0.5 mmol) in THF (5 ml), was added NaH (14 mg, 0.64 mmol) and the solution cooled to −78° C. Tetrahydrofuran-2-yl)methanol (51 mg, 0.48 mmol) was added dropwise as a solution in THF (1 ml), and the solution stirred for 1 h at −78° C., then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by silica gel chromatography (hexane/EtOAc) to give 23 mg of 4,6-dichloro-2-((tetrahydrofuran-2-yl)methoxy)pyrimidine. This was dissolved in DMF (3 ml), NaH (6 mg) was added, followed by 5-(3-methoxyphenyl)-1H-pyrazole (16 mg) and the reaction mixture stirred for 1 h at RT. Morpholine (9 ul) was added, and the reaction stirred overnight at rt, then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by LC/MS to give 6 mg of 4-(6-(3-(3-methoxyphenyl)-1H-pyrazol-1-yl)-2-((tetrahydrofuran-2-yl)methoxy)pyrimidin-4-yl)morpholine, Compound 2.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.90 min, (M+H)+ 438
-
- To a solution of Intermediate I, 4,6-dichloro-2-(methylsulfonyl)pyrimidine (113 mg, 0.5 mmol) in THF (5 ml), was added NaH (14 mg, 0.64 mmol) and the solution cooled to −78° C. 2-(tetrahydro-2H-pyran-4-yl)ethan-1-ol (65 mg) was added dropwise as a solution in THF (1 ml), and the solution stirred for 1 h at −78° C., then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by silica gel chromatography (hexane/EtOAc) to give 65 mg of 4-(2-(3,5-dichlorophenoxy)ethyl)tetrahydro-2H-pyran. This was dissolved in DMF (3 ml), NaH (9 mg) was added, followed by 5-(3-methoxyphenyl)-1H-pyrazole (41 mg) and the reaction mixture stirred for 1 h at RT. Morpholine (21 ul) was added, and the reaction stirred overnight at rt, then quenched with water, extracted with EtOAc, dried (MgSO4), filtered, evaporated and purified by LC/MS to give 9 mg of 4-(6-(3-(3-methoxyphenyl)-1H-pyrazol-1-yl)-2-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)pyrimidin-4-yl)morpholine, Compound 3.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=4.14 min, (M+H)+ 466
-
- Compound 4 was prepared by a method analogous to that for Compound 1, except Intermediate III was used in place of morpholine and 5-phenyl-1H-pyrazole was used in place of 5-(3-methoxyphenyl)-1H-pyrazole.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.16 min, (M+H)+ 455
-
- Compound 5 was prepared by a method analogous to that for Compound 1, except 2-(tert-butoxy)ethan-1-ol was added instead of tetrahydrofuran-2-yl)methanol, and the end product was treated with trifluoroacetic acid (TFA)/DCM 1:2 for 1 h at RT and evaporated prior to purification by LC/MS.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.16 min, (M+H)+ 424
-
- Compound 6 was prepared by a method analogous to that for Compound 1, except 2-(4-methylthiazol-5-yl)ethan-1-ol was added instead of tetrahydrofuran-2-yl)methanol.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.60 min, (M+H)+ 505
-
- Compound 7 was prepared by a method analogous to that for Compound 6, except morpholine was used in place of Intermediate III.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.56 min, (M+H)+ 479
-
- To a solution of Intermediate I, (113 mg, 0.5 mmol) in THF (5 ml) was added NaH (18.4 mg, 0.8 mmol) and the temperature lowered to −78° C. 2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol 71 ul, 0.5 mmol) in THF (1 ml) was added dropwise and the reaction stirred at 1 h at −78° C., worked up by quenching with water, extraction with EtOAc, dried (MgSO4), filtered and evaporated. Dissolved in THF (3 ml), 3-(3-methoxyphenyl)-1H-pyrazole (18 mg) and NaH (7.5 mg) were added, and the reaction was stirred for 1 h at rt. Intermediate III (35 mg) was added, and the reaction stirred overnight at rt. Quenched with water, evaporated and purified on HPLC, then treated with TFA/DCM 1:2 (0.5 ml), evaporated and purified by LC/MS to give 6 mg of 4-(3-((3aR,6aR)-hexahydro-4H-furo[3,2-b]pyrrol-4-yl)-5-(3-(3-methoxyphenyl)-1H-pyrazol-1-yl)phenoxy)butane-1,2-diol (Compound 8).
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.20 min, (M+H)+ 468
-
- Compound 9 was prepared by a method analogous to that for Compound 8, except morpholine was used in place of Intermediate III.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.18 min, (M+H)+ 442
-
- To a solution of Intermediate II (27 mg, 0.1 mmol) in DMF (1 ml) was added Cs2CO3 (65 mg, 0.2 mmol), followed by 5-phenyl-1H-imidazole (5 mg, 0.1 mmol). The reaction was stirred for 70 min at RT, and morpholine (30 ul) was added and the reaction stirred for 60 min. The mixture was evaporated and purified by LC/MS to give 18 mg of 4-(6-(4-phenyl-1H-imidazol-1-yl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine (Compound 10).
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.18 min, (M+H)+ 429
-
- 400 mg of 4-(m-tolyl)thiazole was treated with LDA (1.1 eq) and bromine (1.5 eq) to give 2-bromo-4-(m-tolyl)thiazole. 2-bromo-4-(m-tolyl)thiazole was further converted to (3aR,6aR)-4-(2-((tetrahydrofuran-2-yl)methoxy)-6-(4-(m-tolyl)thiazol-2-yl)pyrimidin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole (Compound 11) as illustrated in the scheme above. 4 mg of product was obtained.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.78 min, (M+H)+ 465 Example 12: Synthesis of 4-(2-((tetrahydrofuran-2-yl)methoxy)-6-(4-(m-tolyl)thiazol-2-yl)pyrimidin-4-yl)morpholine (Compound 12)
-
- Compound 12 was prepared by a method analogous to that for Compound 11, except Intermediate VI was added instead of Intermediate V.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=2.18 min, (M+H)+ 439
- 1H NMR (300 MHz MeOD): δ 8.26 (s, 1H), 7.86 (m, 2H), 7.38 (m, 2H), 7.24 (s, 1H), 3.35 (m, 3H), 3.94 (m, 1H), 3.80 (m, 9H), 2.47 (s, 3H), 2.01 (m, 4H)
-
- To 200 mg of Intermediate VI in degassed dioxane (10 ml) was added Na2CO3 (1.5 eq), Pd(PPh3)4 (0.1 eq) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.3 eq). The reaction was stirred at 100° C. for 2 h under argon. The mixture was evaporated, re-dissolved in EtOAc, washed (saturated aq. sodium bicarbonate), dried (MgSO4), filtered and evaporated. Re-dissolved in DMF (10 ml), 3-bromotoluene (30 eq), CuI (1 eq) and Cs2CO3 (1.1 eq) were added, and the mixture heated at 160° C. for 4 h. The mixture was evaporated, re-dissolved in EtOAc, washed (saturated aq. bicarbonate), dried (MgSO4), filtered, evaporated, and purified by LC/MS to give 147 mg of Compound 13.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=1.52 min, (M+H)+ 422
- 1H NMR (300 MHz MeOD): δ 8.28 (s, 1H), 7.71 (s, 1H), 7.65 (m, 1H), 7.39 (m, 1H), 7.21 (d, 1H), 7.11 (m, 2H), 4.39 (m, 3H), 3.93 (m, 1H), 3.78 (m, 9H), 2.49 (s, 3H), 2.00 (m, 4H)
-
- To Intermediate VII in THF was added NaH (3.1 eq.) and 1,4-oxepane (3 eq). The mixture was stirred at RT for 2 h. Purified by LC/MS to give Compound 14.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.19 min, (M+H)+ 436
- 1H NMR (300 MHz CDCl3): δ 8.60 (s, 1H), 7.79 (s, 1H), 7.73 (m, 1H), 7.35 (m, 1H), 7.20 (m, 1H) 6.88 (s, 1H), 6.76 (s, 1H), 4.43 (m, 1H), 4.34 (m, 2H), 3.90 (m, 7H), 3.77 (m, 3H), 2.46 (s, 3H), 2.12 (m, 3H), 1.99 (m, 2H), 1.83 (m, 1H)
-
- Compound 15 was prepared by a method analogous to that for Compound 14.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.71 min, (M+H)+ 436
- 1H NMR (300 MHz CDCl3): δ 8.58 (s, 1H), 7.78 (s, 1H), 7.72 (m, 1H), 7.34 (m, 1H), 7.20 (m, 1H), 6.71 (d, 2H), 4.48 (m, 1H), 4.35 (m, 2H), 4.11 (m, 1H), 3.97 (m, 3H), 3.69 (m, 3H), 3.41 (s, 3H), 2.43 (s, 3H), 2.26 (m, 3H), 2.00 (m, 2H), 1.83 (m, 1H)
-
- Compound 16 was prepared by a method analogous to that for Compound 4, except 5-(3-methoxyphenyl)-1H-pyrazole was added instead of 5-phenyl-1H-pyrazole.
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=3.89 min, (M+H)+ 485
-
- To 100 mg of Intermediate VII in degassed dioxane/water 9:1 was added 2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.2 eq), K2CO3 (1.1 eq) and Pd(dppf)Cl2 (0.3 eq) and the mixture was heated under argon at 90° C. overnight. The mixture was evaporated, re-dissolved in EtOAc and saturated aq. bicarbonate, the layers separated, washed with bicarbonate, dried (MgSO4), filtered, and evaporated. Re-dissolved in EtOH, Pd/C added and hydrogenated for 4 h at RT. Purified by LC/MS.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=2.34 min, (M+H)+ 407
- 1H NMR (300 MHz CDCl3): δ 8.62 (s, 1H), 7.79 (s, 1H), 7.73 (d, 1H), 7.61 (s, 1H), 7.35 (m, 1H), 7.24 (m, 1H), 6.81 (s, 1H), 4.45 (m, 3H), 4.22 (m, 1H), 4.12 (m, 1H), 3.85 (m, 1H), 3.61 (m, 1H), 3.39 (m, 2H), 2.49 (s, 3H), 2.11 (m, 3H), 1.83 (m, 1H)
-
- To 60 mg of Intermediate VII in DMF (4 ml) was added tBuOK (1.1 eq) and 2-methoxyethane-1-thiol (1.2 eq) and the reaction stirred at RT overnight. The mixture was evaporated, re-dissolved in EtOAc, washed with sat aq. NaHCO3, dried (MgSO4), filtered and evaporated. Re-dissolved in DCM (4 ml) and 1.5 eq of mCPBA added, stirred at RT for 4 h, worked up as described for the last step and purified by LC/MS to give Compound 18.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=1.92 min, (M+H)+ 443
- 1H NMR (300 MHz CDCl3): δ 8.61 (1H, s), 8.33 (1H, s), 7.82 (1H, s), 7.71 (1H, m), 7.35 (1H, m), 7.24 (1H, m), 6.86 (1H, s), 4.42 (3H, m), 3.90 (4H, m), 3.47 (4H, m), 3.19 (1H, m), 2.48 (3H, s), 2.08 (3H, m), 1.82 (1H, m)
-
- To 4,6-dichloro-2-(2-(pyrimidin-2-yl)ethyl)pyrimidine (22 mg, 0.09 mmol) in DMF (4 ml) was added 3-(m-tolyl)-1H-pyrazole (47 mg, 0.3 mmol) and NaH (50 mg). The mixture was shaken for 2 h at RT and (3aR,6aR)-hexahydro-412-furo[3,2-b]pyrrole (27 mg, 0.09 mmol) added. The reaction was heated to 80° C. for 4 h and purified by LC/MS to give 7 mg of (3aR,6aR)-4-(6-(3-phenyl-1H-pyrazol-1-yl)-2-(2-(pyrimidin-2-yl)ethyl)pyrimidin-4-yl)hexahydro-2H-furo[3,2-b]pyrrole (Compound 19).
- LC/MS (mobile phase 5-100% ACN in 5 min), Rt=4.02 min, (M+H)+ 454
-
- To 60 mg of Intermediate VIII in DMF (3 ml) was added Cs2CO3 (3 eq) and morpholin-3-ylmethanol (3 eq). The reaction was heated at 100 C for 6 h, evaporated and purified by LC/MS to give 22 mg of Compound 20.
- LC/MS (mobile phase 5-100% ACN in 3 min), Rt=2.03 min, (M+H)+ 450
- 1H NMR (300 MHz DMSO-d6): δ 8.62 (1H, s), 7.80 (2H, m), 7.36 (1H, m), 7.22 (1H, m), 7.03 (2H, m), 4.99 (1H, m), 4.29 (1H, b), 4.08 (1H, d), 3.95 (1H, m), 3.79 (3H, m), 3.55 (4H, m), 3.76 (2H, m), 2.40 (3H, s), 1.98 (3H, m), 1.82 (2H, m), 1.46 (1H, m)
- The activity of Compounds 1-20 was measured using a PIKFYVE assay (luciferase ADP-Glo kinase assay available from Promega Corp. of Madison, Wis.). The activity for each compound is provided in Table 1 below (“A” refers to an IC50 of less than 5 nM, “B” refers to an IC50 of 5-100 nM, “C” refers to an IC50 of 101-1,000 nM, and “D” refers to an IC50 of 1,001-10,000 nM).
-
TABLE 1 PIKFYVE Activity Compound (IC50 in nM) Compound 1 B Compound 2 A Compound 3 A Compound 4 C Compound 5 C Compound 6 B Compound 7 A Compound 8 B Compound 9 A Compound 10 D Compound 11 C Compound 12 B Compound 13 B Compound 14 C Compound 15 D Compound 16 C Compound 17 B Compound 18 D Compound 19 B Compound 20 B - All references cited herein are incorporated by reference.
Claims (58)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/641,159 US20200199136A1 (en) | 2017-08-28 | 2018-08-28 | Pikfyve kinase inhibitors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762551047P | 2017-08-28 | 2017-08-28 | |
PCT/US2018/048369 WO2019046316A1 (en) | 2017-08-28 | 2018-08-28 | Pikfyve kinase inhibitors |
US16/641,159 US20200199136A1 (en) | 2017-08-28 | 2018-08-28 | Pikfyve kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/048369 A-371-Of-International WO2019046316A1 (en) | 2017-08-28 | 2018-08-28 | Pikfyve kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/612,147 Continuation US20240352026A1 (en) | 2017-08-28 | 2024-03-21 | Pikfyve kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200199136A1 true US20200199136A1 (en) | 2020-06-25 |
Family
ID=63668017
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/641,159 Abandoned US20200199136A1 (en) | 2017-08-28 | 2018-08-28 | Pikfyve kinase inhibitors |
US18/612,147 Pending US20240352026A1 (en) | 2017-08-28 | 2024-03-21 | Pikfyve kinase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/612,147 Pending US20240352026A1 (en) | 2017-08-28 | 2024-03-21 | Pikfyve kinase inhibitors |
Country Status (3)
Country | Link |
---|---|
US (2) | US20200199136A1 (en) |
EP (1) | EP3676264A1 (en) |
WO (1) | WO2019046316A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12104159B2 (en) | 2021-06-22 | 2024-10-01 | AcuraStem Incorporated | PIKFYVE antisense oligonucleotides |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020009971A1 (en) | 2018-07-05 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Pikfyve inhibitors |
CN110938078B (en) | 2019-11-25 | 2021-01-01 | 浙江工业大学 | Limited porphyrin Co (II) and preparation method and application thereof |
EP4090426A1 (en) * | 2020-01-13 | 2022-11-23 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
US20230135152A1 (en) | 2020-02-11 | 2023-05-04 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
US20240208964A1 (en) * | 2020-06-03 | 2024-06-27 | Pyridopyrimidines And Methods Of Their Use | Pyridopyrimidines and methods of their use |
EP4165025A4 (en) * | 2020-06-11 | 2024-07-10 | Yumanity Therapeutics Inc | Compositions and methods for the treatment and prevention of neurological disorders |
WO2023215133A1 (en) | 2022-05-02 | 2023-11-09 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
WO2024118515A1 (en) * | 2022-11-28 | 2024-06-06 | Orphai Therapeutics Inc. | Pikfyve inhibitor combination therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150065519A1 (en) * | 2013-08-28 | 2015-03-05 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2432303C (en) * | 2000-12-21 | 2010-04-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
CN1665810A (en) * | 2002-05-30 | 2005-09-07 | 沃泰克斯药物股份有限公司 | Inhibitors of JAK and CDK2 protein kinases |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
ATE496045T1 (en) * | 2007-04-12 | 2011-02-15 | Hoffmann La Roche | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE |
US9481670B2 (en) * | 2011-01-25 | 2016-11-01 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
CA2851082A1 (en) * | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
CN104582707B (en) * | 2012-07-23 | 2017-09-26 | 斯法尔制药私人有限公司 | Triaizine compounds |
US10758545B2 (en) | 2015-06-25 | 2020-09-01 | University Of Southern California | Methods to treat neurological diseases |
US10975081B2 (en) * | 2015-07-23 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors |
-
2018
- 2018-08-28 US US16/641,159 patent/US20200199136A1/en not_active Abandoned
- 2018-08-28 EP EP18773693.9A patent/EP3676264A1/en active Pending
- 2018-08-28 WO PCT/US2018/048369 patent/WO2019046316A1/en unknown
-
2024
- 2024-03-21 US US18/612,147 patent/US20240352026A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150065519A1 (en) * | 2013-08-28 | 2015-03-05 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12104159B2 (en) | 2021-06-22 | 2024-10-01 | AcuraStem Incorporated | PIKFYVE antisense oligonucleotides |
Also Published As
Publication number | Publication date |
---|---|
EP3676264A1 (en) | 2020-07-08 |
US20240352026A1 (en) | 2024-10-24 |
WO2019046316A1 (en) | 2019-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240352026A1 (en) | Pikfyve kinase inhibitors | |
US11008305B2 (en) | DNA-PK inhibitors | |
US11186591B2 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
US10807985B2 (en) | Compositions useful for treating disorders related to kit | |
JP6813665B2 (en) | 4-Pyridone compound or salt thereof, pharmaceutical composition and agent containing it | |
US11542262B2 (en) | Phosphatidylinositol 3-kinase inhibitors | |
US20180201609A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
US20240197747A1 (en) | Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors | |
US9187454B2 (en) | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | |
US20170112833A1 (en) | Tyrosine Kinase Inhibitor And Uses Thereof | |
US11834436B2 (en) | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
US20220017491A1 (en) | Compound inhibiting yap-tead binding, and pharmaceutical composition for preventing or treating cancer, comprising compound as active ingredient | |
US20230135152A1 (en) | Pikfyve kinase inhibitors | |
US10538528B2 (en) | 5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative | |
US11945824B2 (en) | Heterocyclic compounds as anti-viral agents | |
WO2023215133A1 (en) | Pikfyve kinase inhibitors | |
US20230234938A1 (en) | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors | |
US20230382911A1 (en) | Pyrazoleamide derivatives | |
US20240101562A1 (en) | Novel compound, and pharmaceutical composition for preventing or treating resistant cancer, comprising same | |
US20230303562A1 (en) | Pyrazole compound and preparation method therefor and use thereof | |
US20230365525A1 (en) | Antiviral compounds | |
WO2024099225A1 (en) | Ulk inhibitors | |
WO2023196518A1 (en) | Cdk9 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: ACURASTEM INCORPORATED, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SMRCINA, MARTIN;LI, RONGHUA;NAIR, ANIL;AND OTHERS;SIGNING DATES FROM 20220810 TO 20220904;REEL/FRAME:061199/0107 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AMENDMENT AFTER NOTICE OF APPEAL |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |